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Abstract 
 
 
 
The aim of this thesis is to develop a stable generic formulation that is 
bioequivalent to the innovator product Diflucan capsule by Pfizer. 
Diflucan has different trade names; in the local market it is marketed 
as Trican. Diflucan is presented as a capsule form in the world, but as 
a tablet form in the USA. The goal is to develop a tablet form for the 
local market by using a simple and cost effective technology, and at 
the same time to retain the qualitative and quantitative properties of 
the innovator. 
 
In developing the generic formulation, a comprehensive review for the 
available references was made on the drug.  Official and authoritative 
references were used for the pharmaceutical and analytical aspects, 
as well as the different studies performed. 
 
Fluconazole as an active ingredient is not described by the US or 
British Pharmacopoeias. Thus, an in-house method was developed 
for both the active as a substance and as a composition in the final 
product. The analysis is performed using an Merck-Hitachi HPLC 
systems consisting of an autosampler model L-7200, a pump model 
L-7100 and a diode array detector model L-7450A. The column used 
is LiCrospher RP-18 e, 5 m, 250x 4mm, UV set at 261 nm and a 
mobile phase mixture of water:  Methanol (45:55). 
 
The method of analysis was validated. The method was found 
selective for the active to be analyzed. The precesion was found to 
be precise with a coefficient of variation of 0.87 and accurate with a 
percentage of recovery of 99.79. The method was also found linear 
over the range of 60% -140 % with a correlation coefficient of .99995 
and y-intercept of 0.507. Robustness was tested with different 
analysts, different elapsed assay time, different sonicating time, 
different columns and instruments. All results were according to 
specifications. 
 
A tablet form was chosen as it can be mass produced simply and 
quickly and thus the resultant cost is low. Direct compression method 
use the minimum machines of all other tablet forms, as no granulation 
is performed. The excepients used in the formulation are inert and 
widely used in direct compression tablets. Flowability, compressibility, 
disintegration and dissolution were tested on different types and 
percentages of excepients to select the suitable type and percentage. 
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The direct compression method was found very effective and the 
resultant tablet were within the predetermined specification. 
 
A comparative dissolution profile was made for the formulated (Dican) 
tablet vs the brand product Trican capsule. The similarity factor 
calculation was applied. When calculating the similarity factor in the 
range 10 – 25 minutes, the result fails (f2 = 44.1). This is due to the 
capsule shell of Trican, which delays the dissolution in the first 5 
minutes. The similarity factor calculated in the range 15 – 25 minutes 
was found to be within limits (f2=51.2). 
 
The stability of the formulated tablet at accelerated conditions of 
T=40 ºC, RH= 75 and T=30 ºC, RH= 60  were studied for six months. 
The light effect was also studied for seven months. Samples were 
tested for appearance, assay, dissolution and hardness. The results 
indicate that no significant changes occurred and the product was 
stable at these conditions. 
 
A bioequivalence study was performed for Dican tablets vs Diflucan 
capsules in Tanta University, Egypt. The peak plasma concentration 
(Cmax) of Fluconazole following the administration of two Dican tablets 
ranged from 1.748 – 5.021 g/ml with a mean value of 3.088 ± 0.796 
g/ml whereas, the Cmax of Fluconazole following the administration of 
one Diflucan capsule (Pfizer) ranged from 1.636 – 5.707 g/ml, with a 
mean value of 2.777 ± 0.999 g/ml. The mean time to reach the peak 
concentration (tmax) was 1.979 ± 1.386 hr after administration of two 
Dican tablets and 3.395 ± 1.763 hr after administration of one 
Diflucan capsule. The area under the plasma concentration time 
curve (AUC0∞)  after administration of two Dican tablet ranged from 
78.09 – 226.05 g.hr/ml, with a mean value of  142.5 ± 39.47 
g.hr/ml, while following administration of one Diflucan capsule, it 
ranged from 76.55 – 310.2 g.hr/ml, with a mean value of 149.3 ± 
60.333 g.hr/ml. Relative Bioavailability = 95.44 % (as calculated 
from the AUC. 
 
A potency test for Fluconazole was developed using the plate method 
using Candida Albicans as the test organism. The obtained results 
indicate that Dican tablet activity against Candida albicans is 103.1% 
compared to Trican capsule. The antimicrobial activity of Fluconazole 
was tested agaist 4 bacterial strains using MIC method. Salmonella, 
Staphylococcus Aureus, Pseudomonas Aeruginosa and Escherishia 
Coli were used. Fluconazole has activity against Staphylococcus 
Aureus using the MIC method. 250 μg/ml of Fluconazole was active 
against 4.4 x 103 microorganisms / ml of Staphylococcus Aureus in 
VII 
tryptic soy broth (TSB). The results were compared from that 
obtained from Clarithromycin, an antibiotic indicated for 
Staphylococcus Aureus. 36.5 μg/ml Clarithromycin was active against 
4.4 x 103   microorganisms / ml of Staphylococcus Aureus in tryptic 
soy broth (TSB). Thus, Fluconazole has an activity of 14.6 % as 
compared to Clarithromycin. 
 
Fluconazole didn’t show activity against Salmonella (up to 1000 μg/ml 
against 1.25 x 103 bacteria / ml), against Pseudomonas Aeruginosa 
(up to 1000 μg/ml against 4.3 x 103 bacteria / ml) and against 
Escherishia Coli (up to 1000 μg/ml against 2.9 x 103 bacteria / ml). 
 IIIV
 
 الخلاصة
 
اْ اٌٙذف ِٓ ٘زٖ اٌذساعخ ٘ٛ رطٛ٠ش رشو١جخ دٚائ١خ ثبثزخ رىْٛ ِىبفئخ د١ٛ٠ب ٌٍّغزذضش 
ٌذ٠فٍٛوبْ ػذح اعّبء رجبس٠خ فٟ اٌؼبٌُ، فٙٛ . الاطٍٟ د٠فٍٛوبْ وجغٛلاد ٌششوخ ثفب٠ضس
ٚ ٠غٛق اٌذ٠فٍٛوبْ فٟ اٌؼبٌُ ػٍٝ شىً . ٠غٛق فٟ اٌغٛق اٌّذٍٟ رذذ اعُ رشا٠ىبْ
اٌغب٠خ ٘ٛ رطٛ٠ش رشو١جخ ػٍٝ شىً . وجغٛلاد ٚفٟ اٌٛلا٠بد اٌّزذذح ػٍٝ شىً دجٛة
دجٛة ٌٍغٛق اٌّذٍٟ ثبعزخذاَ رىٌٕٛٛج١ب ثغ١طخ ٚ لٍ١ٍخ اٌزىبٌ١ف ٚ فٟ ٔفظ اٌٛلذ 
. رذبفع ػٍٝ اٌظفبد اٌىّ١خ ٚ إٌٛػ١خ ٌٍّغزذضش الاطٍٟ
 
اثٕبء رطٛ٠ش ٘زٖ اٌزشو١جخ رّذ ِشاجؼخ شبٍِخ ٌٍّشاجغ ٚ اٌّمبلاد اٌّزٛفشح ػٓ 
اٌّغزذضش الاَ ٚاعزخذِذ اٌّشاجغ اٌّظذلخ ٚ اٌّؼزّذح فٟ ِجبلاد اٌظ١ذٌخ ٚ 
. اٌزذٍ١ً
 
اْ اٌفٍٛوبٔبصٚي وّبدح فؼبٌخ غ١ش ِٛطٛف فٟ دعبر١ش الادٚ٠خ الاِش٠ى١خ اٚ اٌجش٠طبٔ١خ ٚ 
دح خبَ ٚ فٟ اٌّغزذضش اثبٌزبٌٟ وبْ ٕ٘بن اٌذبجخ اٌٝ رطٛ٠ش طش٠مخ رذٍ١ً ٌٙب وُ
 ٚ اٌّىْٛ ِٓ اخز ػ١ٕبد ihcatiH kcreM ِٓ ٔٛع CLPHثبعزخذاَ جٙبص .إٌٙبئٟ
 ٚ جٙبص ل١بط  ٌلاشؼخ اٌفٛق ثٕفغج١خ 0017- ، ِضخخ ِٓ ٔٛع ي0027-رارٟ ٔٛع ي
 ٍُِ ِٓ ٔٛع 4 ٍُِ ٚلطشٖ 052اعزخذَ ػّٛد طٌٛٗ .  أ0547-ِزؼذد اٌّٛجبد ٔٛع ي
.  ِب٠ىشْٚ5 رسح  ثمطش 81ٌ١ىشٚعف١ش ِؼجأ ثزساد اٌغ١ٍ١ىب ِؼذٌخ ثغٍغٍخ وشثٛٔ١خ ِٓ 
 ٚ اٌغبئً اٌّغزخذَ ٘ٛ ِبء ٚ ِ١ثبٔٛي ثٕغجخ 162طٛي اٌّٛجخ اٌزٟ اعزخذِذ ٟ٘ 
). 54:55(
 
ٌخ اٌّشاد افمذ ٚجذد اٌطش٠مخ أزمبئ١خ ٌٍّبدح اٌفغ. ٌمذ رُ اٌزذمك ِٓ اٌزثجز١خ ٌطش٠مخ اٌزذٍ١ً
 وّب اْ إٌزبئج 78،0 ٘ٛ اخزلافٙبٚ لذ ٚجذد إٌزبئج ِزمبسثخ ِٓ ثؼضٙب ٚػبًِ . رذٍ١ٍٙب
ٚ لذ ٚجذد اٌطش٠مخ راد ػلالخ خط١خ ػٍٝ %. 79.99وبٔذ دل١مخ ٚ ػبًِ اٌذلخ ف١ٙب 
 ٚٔمطخ رمبطغ ِغ اٌّذٛس اٌؼّٛدٞ ص 59999.0ٚػبًِ رشاثظ %  041%-06ِذٜ 
وّب رُ فذض لبثٍ١خ اٌطش٠مخ ٌّزغ١شاد ػذح ِثً اٌّذًٍ، ِذح رذٍ١ً ِخزٍفخ، ِذح . 705.0
وً إٌزبئج وبٔذ دغت اٌّٛاطفبد . رذض١ش ِخزٍفخ، اػّذح ٚ اجٙضح ِخزٍفخ
. اٌّٛضٛػخ
 
اْ . ٌمذ اخز١شد اٌذجٛة وشىً ط١ذلأٟ ٌغٌٙٛخ ٚ عشػخ أزبجٗ  ٚثبٌزبٌٟ رىبٌ١ف الً
طش٠مخ اٌىجظ اٌّجبشش فٟ رظٕ١غ اٌذجٛة رغزخذَ الً الاجٙضح اٌزظٕ١ؼ١خ ِمبسٔخ 
ٌمذ فذظذ . ثبٌطشق الاخشٜ د١ث أٗ لا رٛجذ ػٍّ١خ اٌزذجت لجً ػٍّ١خ وجظ اٌذجٛة
ٌمذ . اٌزذفم١خ ٚ ػبًِ اٌىجظ ٚاٌزفىه ٚ اٌزذًٍ ثبعزخذاَ ِٛاد ِخزٍفخ ٚ ٔغت ِخزٍفخ
. ٚجذد ٘زٖ اٌطش٠مخ فؼبٌخ ٚ اٌذجٛة إٌبرجخ رمغ ضّٓ اٌّٛاطفبد اٌّذذدح ِغجمب
 
. ٌمذ رّذ دساعخ ِٕذٕٝ اٌزذًٍ اٌّخجشٞ ٌٍذجٛة إٌّزجخ ِمبسٔخ ِغ اٌىجغٛلاد الاطٍ١خ
 ٚ ٘ٛ ادٔٝ ِٓ  دل١مخ52-01 فٟ اٌّذٜ ث١ٓ 1.44 اْ ػبًِ رشبثٗ ِٕذٕ١ٟ اٌزذًٍ ٠غبٚٞ
 XI
 ٚ ٘زا ٔبرج ػٓ ربث١ش اٌىجغٌٛخ اٌفبسغخ فٟ اٌزشا٠ىبْ وجغٛلاد د١ث اٌذذ اٌّغّٛح ثٗ
اْ ٘زٖ إٌز١جخ رزغ١ش فٟ اٌّذٜ ث١ٓ . أٙب رؤخش ػٍّ١خ اٌزذًٍ فٟ اٌخّغخ دلبئك الاٌٚٝ
. أٞ ضّٓ اٌذذٚد اٌّغّٛح ثٙب 2.15  دل١مخ ٌزظجخ52-51
 
ٌمذ اجش٠ذ دساعخ اٌثجبر١خ ػٍٝ اٌذجٛة إٌّزجخ ثٛضؼٙب فٟ ظشٚف اٌذساعخ اٌّزغبسػخ 
 03 ٚ فٟ ظشف اخش ػٍٝ دشاسح 57 دسجخ ِئٛ٠خ ٚ سطٛثخ ٔغج١خ 04ػٍٝ دشاسح 
ٚ ٌمذ رّذ دساعخ ربث١ش اٌضٛء ثزؼش٠ض .  ٌّذح عزخ اشٙش06دسجخ ِئٛ٠خ ٚ سطٛ٠خ 
اْ إٌزبئج رظٙش ػذَ ٚجٛد رغ١١ش .  عبػخ ٠ِٛ١ب ٌّذح عجؼخ شٙٛس42اٌذجٛة ٌٍضٛء 
. ٠زوش فٟ ٘زٖ اٌظشٚف ػٍٝ ِٛاطفبد اٌّغذضش
 
وٍ١خ اٌظ١ذٌخ / وّب اجش٠ذ ػٍٝ اٌّغزذضش دساعخ اٌزىبفؤ اٌذ١ٛٞ فٟ جبِؼخ طٕطب 
 xamCٌمذ ٚجذد . ثجّٙٛس٠خ ِظش ِمبسٔخ ِغ د٠فٍٛوبْ وجغٛلاد ٌششوخ ثفب٠ضس
 - 847.1ٌٍفٍٛوٛٔبصٚي فٟ اٌذَ ثؼذ رٕبٚي دجز١ٓ ِٓ اٌذجٛة إٌّزجخ رزشاٚح ث١ٓ 
ًِ ث١ّٕب وبٔذ ثؼذ /  ِب٠ىشٚغشاَ120.3 ± 697.0ًِ ثّزٛعظ /  ِب٠ىشٚغشاَ120.5
ًِ /  ِب٠ىشٚغشاَ 707.5 - 636.1رٕبٚي وجغٌٛخ ٚادذح ِٓ د٠فٍٛوبْ رزشاٚح ث١ٓ 
 ٌٍفٍٛوٛٔبصٚي فٟ اٌذَ xamtاِب ِزٛعظ اي . ًِ/  ِب٠ىشٚغشاَ777.2 ± 999.0ثّزٛعظ 
 عبػخ ث١ّٕب وبٔذ ثؼذ رٕبٚي 979.1 ± 683.1ثؼذ رٕبٚي دجز١ٓ ِٓ اٌذجٛة فىبٔذ 
اِب اٌّغبدخ رذذ إٌّذٕٝ .   عبػخ593.3 ± 367.1وجغٌٛخ ٚادذح ِٓ د٠فٍٛوبْ 
 90.87 - 50.622 فىبٔذ ثؼذ رٕبٚي دجز١ٓ ِٓ اٌذجٛة إٌّزجخ رزشاٚح ث١ٓ CUA
ًِ ث١ّٕب وبٔذ / عبػخ . ِب٠ىشٚغشاَ5.241 ± 74.93ًِ ثّزٛعظ / عبػخ.ِب٠ىشٚغشاَ
 20.013 - 55.67ثؼذ رٕبٚي وجغٌٛخ ٚادذح ِٓ د٠فٍٛوبْ رزشاٚح ث١ٓ 
اٌزىبفؤ . ًِ/ عبػخ . ِب٠ىشٚغشاَ3.941 ± 333.06ًِ ثّزٛعظ / عبػخ .ِب٠ىشٚغشاَ
. ػٕذ دغبثٗ ِٓ اٌّغبدخ رذذ إٌّذٕٝ% 44.59إٌغجٟ ٠غبٚٞ 
 
وّب رُ رطٛ٠ش طش٠مخ ث١ٌٛٛج١خ ٌذغبة اٌفؼبٌ١خ ٌٍفٍٛوٛٔبصٚي رؼزّذ ػٍٝ طش٠مخ 
 ٚ رُ ِمبسٔخ فؼبٌ١خ  )snaciblA adidnaC(ثبعزخذاَ  )dohtem etalp(اٌظذْٛ 
ٚفٟ رجشثخ اخشٜ %.  1.301اٌذجٛة إٌّزجخ ِغ وجغٛلاد د٠فٍٛوبْ ٚوبٔذ إٌز١جخ 
. )CIM(رُ دساعخ فؼبٌ١خ ِبدح اٌفٍٛوٛٔبصٚي ضذ اسثغ أٛاع ثىز١ش٠خ ثبعزخذاَ طش٠مخ 
 ,asonigureA sanomoduesP: اٌجىز١ش٠ب اٌزٟ اعزؼٍّذ ٌٍذساعخ ٟ٘
ٌمذ ٚجذ اْ ٌٍفٍٛوٛٔبصٚي . ,iloC .E ,allenomlaS ,sueruA succocolyhpatS
ًِ ِٕؼذ ّٔٛ /  ِب٠ىشٚغشاَ 052 د١ث اْ sueruA succocolyhpatSفؼبٌ١خ ضذ 
 x 4.4
3
ٚ لذ لٛسٔذ ٘زٖ إٌز١جخ ِغ رٍه اٌزٟ . )BST( ثبعزخذاَ ًِ /   ِٓ اٌجىز١ش٠ب01
 ِب٠ىشٚغشاَ 5.63دظً ػٍ١ٙب ثبعزخذاَ ولاس٠ثشِٚب٠غ١ٓ رذذ ٔفظ اٌظشٚف د١ث اْ 
 x 4.4ًِ ِٕؼذ ّٔٛ / 
3
 ٚثبٌزبٌٟ فبْ اٌفؼبٌ١خ ٌٍفٍٛوٛٔبصٚي ًِ / ِٓ اٌجىز١ش٠ب  01
%.  6.41ِمبسٔخ ِغ اٌىلاس٠ثشِٚب٠غ١ٓ ٟ٘ دٛاٌٟ 
 
اعزخذِذ رشاو١ض ٚطٍذ  ( allenomlaSاْ ِبدح اٌفٍٛوٛٔبصٚي ٌُ رظٙش فؼبٌ١خ ضذ اي 
 x 52.1ًِ ضذ /  ِب٠ىشٚغشاَ 0001اٌٝ 
3
، اٚضذ اي )ًِ/ ِٓ اٌجىز١ش٠ب01
/  ِب٠ىشٚغشاَ 0001اعزخذِذ رشاو١ض ٚطٍذ اٌٝ ( asonigureA sanomoduesP
 X
 x 3.4ًِ ضذ 
3
اعزخذِذ رشاو١ض ٚطٍذ ( iloC .E، اٚضذ اي )ًِ /  ِٓ اٌجىز١ش٠ب01
 x 9.2ًِ ضذ /  ِب٠ىشٚغشاَ 0001اٌٝ 
3
.)ًِ /  ِٓ اٌجىز١ش٠ب01
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PART I  INTRODUCTION 
 
 
I -1  Mode of Action.
( 1 , 2 ,5 ,1 5 )  
 
 
Fluconazole is the first of a new subclass of synthetic triazole 
antifungal agents. It is designated chemically as 2,4-difluoro-a,a1-
bis(1H-1,2,4-triazol-1-ylmethyl) benzyl alcohol with an empirical 
formula of C13H12F2N6O and Molecular Weight 306.3. It is a white 
crystalline solid which is slightly soluble in water and saline. 
 
 
 
 
 
 
Figure I-1: Structure of Fluconazole 
 
 
The only marketed product, active by oral route, similar to 
Fluconazole, is Ketoconazole. Fluconazole has the following 
advantages over Ketoconazole: 
1. Therapeutic doses 4-8 times less (Fluconazole = 50 mg / day; 
Ketoconazole = 200 – 400 mg / day) 
2. Fluconazole does not produce alternation in the hepatic 
enzymes production. 
3. Fluconazole does not alter the hematic levels of testosterone. 
4. Fluconazole presents an excellent penetration in the 
cerebrospinal fluid and this assures great possibilities for the 
SNC-micosis treatment. 
 
Fluconazole is a highly selective inhibitor of fungal cytochrome P-450 
sterol C-14 alpha-demethylation. Mammalian cell demethylation is 
much less sensitive to Fluconazole inhibition. The subsequent loss of 
normal sterols correlates with the accumulation of 14 alpha-methyl 
sterols in fungi and may be responsible for the fungistatic activity of 
Fluconazole. 
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I-2  Pharmacokinetics and Metabolism 
(1,5,15, 21)
 
 
 
The pharmacokinetic properties of Fluconazole are similar following 
administration by the intravenous or oral routes. In normal volunteers, 
the bioavailability of orally administered Fluconazole is over 90% 
compared with intravenous administration.  
Peak plasma concentrations (Cmax) in fasted normal volunteers occur 
between 1 and 2 hours with a terminal plasma elimination half-life of 
approximately 30 hours (range: 20-50 hours) after oral administration. 
In fasted normal volunteers, administration of a single oral 400 mg 
dose of  Fluconazole leads to a mean Cmax of 6.72 µg/ml (range: 
4.12 to 8.08 µg/ml) and after single oral doses of 50-400 mg, 
Fluconazole plasma concentrations and AUC (area under the plasma 
concentration-time curve) are dose proportional. 
Steady-state concentrations are reached within 5-10 days following 
oral doses of 50-400 mg given once daily. Administration of a loading 
dose (on day 1) of twice the usual daily dose results in plasma 
concentrations close to steady-state by the second day. The apparent 
volume of distribution of Fluconazole approximates that of total body 
water. Plasma protein binding is low (11-12%). Following either 
single- or multiple-oral doses for up to 14 days, Fluconazole 
penetrates into all body fluids studied (see table (I-1)). In normal 
volunteers, saliva concentrations of Fluconazole were equal to or 
slightly greater than plasma concentrations regardless of dose, route, 
or duration of dosing.  
 
Table I-1: Ratio of Fluconazole Tissue (Fluid)/Plasma Concentration 
 
Tissue or Fluid Ratio  
Cerebrospinal fluid 0.5-0.9 
Saliva  1 
Sputum  1 
Blister fluid  1 
Urine  10 
Normal skin  10 
Nails  1 
Blister skin  2 
Vaginal tissue  1 
Vaginal fluid  0.4-0.7 
 
In normal volunteers, Fluconazole is cleared primarily by renal 
excretion, with approximately 80% of the administered dose 
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appearing in the urine as unchanged drug. About 11% of the dose is 
excreted in the urine as metabolites. 
 
The pharmacokinetics of Fluconazole are markedly affected by 
reduction in renal function. There is an inverse relationship between 
the elimination half-life and creatinine clearance. The dose of 
Fluconazole may need to be reduced in patients with impaired renal 
function.  
 
Fluconazole is presented as tablets, powder for oral suspension, or 
injections.  
 
In Palestine, Fluconazole is presented as capsules.(14) 
 
 
I -3 Microbiology 
( 1 ,5 ,15 ,  21 )
 
 
 
Fluconazole exhibits in-vitro activity against Cryptococcus 
neoformans and Candida spp. Fungistatic activity has also been 
demonstrated in normal and immunocompromised animal models for 
systemic and intracranial fungal infections due to Cryptococcus 
neoformans and for systemic infections due to Candida albicans. 
 
Together with other azole antifungal agents, most fungi show a higher 
apparent sensitivity to Fluconazole in vivo than in vitro. Fluconazole 
administered orally and/or intravenously was active in a variety of 
animal models of fungal infection using standard laboratory strains of 
fungi.  
Oral Fluconazole has shown to be active in an animal model of 
vaginal candidiasis. 
 
 
I -4 Indications And Usage
( 1 , 5 , 15 )
 
 
Fluconazole is indicated for the treatment of: 
a-  Vaginal candidiasis (vaginal yeast infections due to Candida). 
b- Oropharyngeal and esophageal candidiasis. In open  
noncomparative studies of relatively small numbers of patients, 
Fluconazole was also effective for the treatment of Candidaurinary 
tract infections, peritonitis, and systemic Candida infections 
including candidemia, disseminated candidiasis, and pneumonia. 
c- Cryptococcal meningitis.  
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I-5 Quantitative and Qualitative Determination 
(7,8,9,10)  
 
 
Fluconazole is not listed in the United States Pharmacopoeia or in the 
British Pharmacopoeia. A development for a quantitative and 
qualitative method of analysis is necessary. The preferred method for 
analysis of Pharmaceutical preparations is the HPLC (High 
Performance Liquid Chromatography), as most pharmaceuticals can 
be separated by HPLC system. Most preparations have a UV maxima 
and so,  a UV/Visible detector is mostly used in the HPLC analysis. 
HPLC is considered to be fast, reproducible, sensitive, easy to work 
with, cost effective and available in the market.  
 
I -5-1 Quanti tat ive Determination (Assay):  
 
 
This is done by preparing a ―Sample‖ and a ―Standard‖. They are 
then injected separately in the HPLC system. ―Area under the 
Peak‖ is determined for each and the following formula is used to 
calculate the percentage of active material in the sample. 
 
 Area of the Sample 
                  % Active =    x 100  
Area of the Standard 
 
 
I-5-2 Qualitative Determination (Identification) 
 
 
This is done by comparing the Retention Time tR of the ―Sample‖ 
and the ―Standard‖. They should be similar. 
 
I-5-3 Important Parameters in Separation Process: 
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Figure I-2: Peak separation and identification 
 
 
Figure (I-2) illustrates the most important parameters in identification 
and separation of different peaks.  
 
t0: Elution time of an unretained component.  
tR: Retention time of each molecule. At the same conditions 
and when separation occurs, each molecule has different 
retention time. Thus, retention time is used for the 
identification of the molecule. 
W: Peak width at base. 
 
 
a- Resolution (R) 
The resolution is an indication for separation. For example: 
Peak A with tR(A) 
Peak B with tR(B) 
 
The resolution R can be calculated by the following formula: 
 
tR(B) - tR(A) 
R = 2   
WA + WB 
 
Where: 
tR(A) = Retention time of peak A 
tR(B) = Retention time of peak B 
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WA = Width of peak A 
WB = Width of peak B 
 
For equal areas: R = 1.5 gives baseline separation 
b- Peak Symmetry (S): 
 
Another important parameter is the peak symmetry, which is 
calculated by the following formula: 
 
A 
S =      
B 
 
Where A and B are illustrated in (figure I-3).  
S = 1.0-1.05 gives the best symmetry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I-3: Peak symmetry 
 
 
I -6  Types of Tablets
( 3 ,  1 7 )
 
 
A tablet form was chosen as it can be mass produced simply and 
quickly and thus the resultant cost is low. Direct compression method 
use the minimum machines of all other tablet methods, as no 
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granulation is performed and thus saving time, personnel and 
machines. 
 
There are many types of tablet depending on their use: 
 Those intended to be swallowed as a whole (coated and non-
coated). 
 Those intended to allow dispersion or dissolution in water prior 
to administration e.g. effervescent, dispersible. 
 Chewable. 
 Sublingual. 
 Eextended Release. 
 Enteric coated (delayed release). 
 
As the pharmacokinetic data indicates, Fluconazole can be presented 
as tablets intended to be swallowed as a whole. 
 
 
I -7  Dissolut ion of The Active Ingredient f rom the 
Dosage Form
(7 ,8 ,11 ,12 ,  17 )
 
 
 
Dissolution rate may be defined as the amount of drug substance that 
goes in solution per unit time under standardized conditions of 
liquid/solid interface, temperature and solvent composition.  
 
Factors that affect the dissolution rate of dosage form can be 
classified into the following categories: 
 
I-7-1 Physiochemical properties of the drug substance. 
 
 
The best equation that describes the physiochemical properties 
is the modified Noyes-Whitney equation: 
 
dc/dt = KA (Cs –Ct) 
 
Where:  
dc/dt: Rate of dissolution, where c is the mass of solute that has 
passed into solution in time t. 
K : Dissolution constant, 
A : Effective surface area of drug particle, 
Cs: Saturated solubility of the drug in the diffusion layer 
Ct:  the concentration of drug at time t. 
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I-7-2  Choice of excepients  
 
 
Diluents, binders, disintegrants, lubricants, surfactants and 
coating materials play all an important  role in the dissolution 
rate. 
 
  
I-7-3  The manufacturing process 
 
 
In addition to the excepient effect, the manufacturing 
process plays also an important role. Method of granulation, 
granules size, moisture content and age of granules as well 
as the compression force utilized in the tabletting process, all 
affect the dissolution rate. 
 
I-7-4  Dissolution apparatus and system 
 
 
The most USP & BP official method for tablets is the rotating 
paddle method. It contains of approximately 1-in diameter X 
1.375 in high. It is made from stainless steel, blade paddle 
rotates at a constant speed of between 25 rpm and 150 rpm 
(It is immersed in 900 (USP) or 1000 (BP) ml of dissolution 
medium in a cylindrical, glass flask of 1000 ml capacity. The 
medium in the flask is kept at a constant temperature of (37 
 0.5) c° by means of a suitable water bath. 
 
The standardized BP conditions for dissolution tests using the paddle 
are:  
a- rotation speed: 50 rpm (paddle)  
b- dissolution medium volume: 900 ml 
c- dissolution medium composition: aqueous, commonly 0.1M HCl 
or phosphate  buffers of pH 6.8 to 7.6 
d-  number of units tested: 6. 
 
The standardized BP acceptance criteria for tests using either the 
basket or the paddle are that, for each unit tested, not less than 70% 
of the active ingredient or ingredients dissolves within 45 minutes. If 
one unit fails to meet this requirement, a retest may be carried out 
using the same number of units; all units in the retest must comply.  
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For developing formulations, an In-vitro dissolution profile is made by 
taking a sample at 10 minutes intervals or less. The dissolution profile 
of the developed formulation is compared with that of the innovative 
drug product at the same conditions, same sample method and using 
the same analysis method. The comparison of the two dissolution 
profile is calculated by the following formulas: 
 
F1 = {[Σn t=1IRt-TtI] / [Σ
n t=1Rt]} x 100 
 
F2 = 50 log {[1+(1/n) Σn t=1(Rt-Tt)
2]-0.5  x 100} 
 
 
Where: 
F1: The percentage difference between the two profiles at each 
sampling point. 
F2: The similarity factor corresponds to the similarity measurement 
between two curves 
n: number of samples 
Rt: The percentage dissolved of the original brand at time t. 
Tt: The percentage dissolved of the trial formulation at time t. 
 
Limits:  
F1 = 0 - 15 
F2=50 - 100 
 
 
I -8  Formulation 
(3 , 17 )
 
 
 
Tablets may be defined as solid pharmaceutical dosage forms 
containing drug substances with or without suitable diluents and 
prepared either by compression or molding methods. 
 
The formulation of Fluconazole tablet (Dican tablet) should be 
designed so that the final tablet will have all essential properties for a 
tablet. Each tablet must contain a known amount of drug and this 
must be checked by content uniformity tests. The tablets must also 
be uniform in weight, appearance and diameter. When they are 
swallowed whole, they should readily disintegrate in the stomach. 
They should be produced with sufficient strength to withstand the 
different stages of processing and packing, and yet be capable of 
rapid breakdown when administered in order to release the drug 
rapidly. The dissolution rate is critical as mentioned above. In 
addition, the tablets should be stable in its proposed packing, when 
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stored at its recommended storage conditions for a reasonable period 
of time. Finally, the tablets should be reasonably robust and be 
capable of withstanding normal patient handling and handling during 
transport.  
 
Several parameters should be taken into consideration during the 
formulation process: dissolution rate, hardness and friability tests, 
weight uniformity and content uniformity to assure homogeneity of the 
drug substance in all tablets within a batch. The assay, identification 
and physical properties tests are important parameters to evaluate 
the resultant specifications. These tests are performed during the 
stability study as well. The results of the stability study are used to 
determine the ability of the packing to protect the product, the suitable 
storage condition and the suitable expiration date for the product. The 
method used for analysis should be validated to insure its linearity, 
selectivity, accuracy, precision, range and robustness. 
 
In the formulation process, the majority of tablets are composed of 
the drug substance and other additives that make the powder system 
more compressible. There are two essential properties in the powder 
intended for compression into tablets; Powder Fluidity and Powder 
Compressibility.  
 
Fluidity is required so that the material can be transported through the 
hopper of a tableting machine. It is also essential so that adequate 
filling of the dies occurs in the tableting machine to produce tablets of 
a consistent weight. Powder flow can be improved mechanically by 
the use of vibrators. However, the use of these devices can cause 
powder segregation. A better method to enhance powder fluidity is to 
incorporate a glidant into formulation. Materials such as fumed silicon 
dioxide (Aerosil) are excellent flow promoters even in concentrations 
of less than 0.01%. Another way to improve powder flow is to make 
the particles as spherical as possible. The most popular method is by 
granulation. 
 
Compressibility is the property of forming a stable, intact compact 
mass when pressure is applied. Some materials compact is better 
than others depending on powder physics of each material. Nearly in 
all cases, granulation improves compressibility of powders. 
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I-8-1 Tablet Preparation Methods 
 
 
The preparation of tablets can be divided into (a) dry methods and (b) 
wet methods.  Dry methods include direct compression, slugging and 
roller compaction, and wet methods include wet granulation.  
 
Direct compression is the most preferred of those methods employing 
liquids, since dry processes do not require the equipment and 
handling expenses required in wetting and drying procedures (cost 
effective) and can avoid hydrolysis of water-sensitive drugs (more 
stable). A direct compression vehicle is an inert substance which can 
be compacted with no difficulty and which may do so even when fairly 
large quantities of drugs are mixed with it.  Materials currently 
available as direct compression diluents may be divided into three 
groups according to their disintegration properties and their flow 
characteristics: 
 
1. Disintegration agents with poor flow, e.g. microcrystalline cellulose 
(Avicel), microfine cellulose and directly compressible starch 
2. Free-flowing materials which do not disintegrate, e.g. dibasic 
calcium phosphate 
3. Free-flowing powders which disintegrate by dissolution, e.g. spray-
dried lactose, anhydrous lactose, spray-crystallized maltose, 
dextrose, sucrose, mannitol and amylose. 
 
Microcrystalline cellulose (Avicel) is perhaps the most widely used 
direct compression excipient. It exhibits the highest compressibility of 
all known direct compression vehicles; however, it has relatively poor 
flow properties.  Avicel is chemically an inert material and is 
compatible with most drugs.   
 
 
I-8-2 Tablet Excipients 
 
A tablet does not just contain the active ingredient but also include 
other substances, known as excipient, which have specific functions.  
Following are the main classes of excipients used: 
 
a- Diluents 
 
 
Diluents or 'bulking agents' are 'Inert' substances which are added to 
the active ingredient in sufficient quantity to make a reasonably sized 
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tablet. This agent may not be necessary if the dose of the drug per 
tablet is high.  Generally, a tablet should weigh at least 50 mg and 
therefore very low dose drugs will invariably require a diluent to bring 
the overall tablet weight to at least 50 mg.  The principal substance 
employed as a diluent is Lactose.  It has a pleasant taste, rapidly 
dissolves in water, absorbs very little moisture and is fairly neutral in 
reaction. Its main disadvantage is that it is somewhat expensive and 
has poor flow characteristics.  Lactose deforms easily under pressure 
and, as a result of this ductility, good tablets are normally produced.  
The spray-dried form of lactose flows much more readily and is used 
as a direct compression vehicle.  Another very popular diluent is 
Microcrystalline Cellulose (Avicel).  It is a nonfibrous form of cellulose 
and is obtained by spraying washed, acid-treated cellulose. It is water 
insoluble, but the material has the ability to draw fluid into the tablet 
by capillary action, thus it swells on contact and acts as a 
disintegrating agent. The material flows well and has a degree of self-
lubricating qualities, thus requiring lower level of lubricant as 
compared to other excepients.  
 
 
b- Binding agents (adhesives) 
 
 
The direct compression method for preparing tablets requires not only 
a free flowing material, but also sufficiently cohesive to act as a 
binder. An example is Avicel, mentioned above, which is a special 
form of cellulose fibril in which the individual crystallites are held 
together largely by hydrogen bonding. It has an excellent 
compression properties. 
 
 
c- Glidants 
 
 
Glidants are materials which are added to tablet formulations in order 
to improve the flow properties of the granulations.  They act by 
reducing interparticulate friction.  The most commonly used and 
effective glidant is fumed (or colloidal) silica.  Flow of granules can be 
dramatically improved by the addition of less than 0. 1% w/w of this 
material to powders and granules.  Fumed silica is thought to act by 
lodging in the surface irregularities of the particles or granules, which 
effectively smoothes the particle surface. 
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d- Lubricants 
 
 
These agents are required to prevent adherence of the granules to 
the punch faces and dies.  They also ensure smooth ejection of the 
tablet from the die.  Many lubricants also enhance the flow properties 
of the granules.  Magnesium stearate is the most popular lubricant 
used and is normally effective on its own as both a die and a punch 
lubricant.  It is incorporated by blending with the dry granules prior to 
compression, up to a concentration of about 5% w/w. A thin layer of 
magnesium stearate around the granule is just as effective as a thick 
layer from the lubrication point of view, but increased magnesium 
stearate quantities reduce the disintegration time, retard drug 
dissolution and also reduce the bonding forces between granules to 
produce soft tablets.  The reduction in drug release properties is due 
to the hydrophobic nature of magnesium stearate preventing drug 
dissolution.   
 
e- Disintegrating agents 
 
 
Disintegrants are always added to tablets to promote breakup of the 
tablets when placed in an aqueous environment.  The object of a 
disintegrant is to cause the tablet to disintegrate rapidly so as to 
increase the surface area of the tablet fragments and so promote 
rapid release of the drug. 
 
Disintegrants can act by swelling in the presence of water to burst 
open the tablet.  Starch is the commonest disintegrant in tablet 
formulation and is believed to act by swelling.  However, other 
effective disintegrants do not swell in contact with water. 
Disintegrants that do not swell exert their disintegrating action by 
capillary action.  Liquid is drawn up through capillary pathways within 
the tablet and ruptures the interparticulate bonds.  This action serves 
to break the tablet apart.  
  
The oldest and still most popular disintegrants are corn and potato 
starch. For rapid disintegration, an amount of 10 to 15% is needed. 
 
A group of super disintegrants have gained in popularity as 
disintegrating agents, because of the low levels (2 to 4%) at which 
they are completely effective. In this group examples are 
croscarmelose or known also as Ac-Di-Sol (cross-linked cellulose), 
crospovidone (cross-linked polymer) and Sodium Starch Glycolate 
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(cross-linked starch). Croscaremelose is the most efficient 
disintegrating agent. 
 
 
I -9  Stabi l i ty Studies  
(4 ,6 )
 
 
 
The purpose of stability testing is to provide evidence on how the 
quality of a drug substance or drug product varies with time under the 
influence of a variety of environmental factors such as: 
1. Temperature. 
2. Humidity.  
3. Light.  
 
Stability testing enables: 
 
1. To select adequate (from the view point of stability) 
formulations and container closure systems. 
2. To determine shelf-life  
3. Storage conditions. 
4. To verify that no changes have been introduced in the 
formulation or manufacturing process that can adversely 
affect the stability of the product. 
 
There are three types of stability testing performed: 
 
I-9-1 Accelerated Testing 
 
 
Studies designed to increase the rate of chemical degradation or 
physical change of an active drug substance or drug product by using 
exaggerated storage conditions as part of the formal, definitive, 
storage program.  
 
These data, in addition to long term stability studies, may also be 
used to assess longer term chemical effects at non-accelerated 
conditions and to evaluate the impact of short term excursions 
outside the label storage conditions such as might occur during 
shipping.  
 
Four climatic zones can be distinguished for the purpose of worldwide 
stability testing: 
 
Zone I : Temperate. 
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Zone II : Sub-tropical with possible high humidity. 
Zone III : Hot/dry. 
Zone IV : Hot/humid. 
 
The following table (I-2) summarize the Storage temperature, 
humidity and period for each climatic zone: 
 
 
 
 
 
Table I-2: Accelerated stability parameters for each climatic zones 
Zone Storage Temp. 
[C]  2C 
Humidity 
[%]  5% 
Period  
[Months] 
III, IV 40 75 6 
I, II 40 75 3 
 
 
I-9-2 Long Term (Real Time) Testing 
 
 
Stability evaluation of the physical, chemical, biological and 
microbiological characteristics of a drug product and a drug 
substance, covering the expected duration of the shelf life and re-test 
period, which are claimed in the submission and will appear on the 
labeling. 
 
The following table ( I-3) summarize the Storage temperature 
and humidity for each climatic zone: 
 
 
Table I-3: Long term stability parameters for each climatic zones 
Zone Storage Temp. 
[C]  2C 
Humidity 
[%]  5% 
I 21 45 
II 25 60 
III 30 35 
IV 30 70 
 
 
I-9-3 On-going Real Time Stability 
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It is the study in post-marketing carried out by the manufacturer 
on production batches according to pre-determined schedule in 
order to confirm the expected shelf life of the product. 
 
Where 'significant change' occurs due to accelerated testing, 
additional testing at an intermediate condition e.g., 30 ºC ± 2 
ºC/60 percent ± 5 percent RH should be conducted. 'Significant 
change' at the accelerated condition is defined as: 
 
1. A 5 percent potency loss from the initial assay value of a 
batch; 
2. Any specified degrades exceeding its specification limit; 
3. The product exceeding its pH limits; 
4. Dissolution exceeding the specification limits for 12 
capsules or tablets. 
5. Failure to meet specifications for appearance and physical 
properties e.g., color, phase separation, re-suspendibility, 
delivery per actuation, caking, hardness, etc. 
 
The long term testing will be continued for a sufficient time 
beyond 12 months to cover shelf life at appropriate test periods.  
 
After evaluation of the stability, the product may be labeled with 
the following storage conditions: 
1. Store at normal storage conditions, at 15 ºC-30 ºC. 
2. Store between 2 ºC– 8 ºC under refrigeration, no freezing. 
3. Store below 8 ºC under refrigeration. 
4. Store in freezer at (-)5 ºC– (-) 20 ºC. 
5. Store below (-)18 ºC in a deep freezer. 
 
General precautionary statements, such as ―protect from light‖ 
and/or ―store in dry place‖, may be included, but should not be 
used to cover up stability problems. 
 
If applicable, recommendations should also be given regarding 
the utilization period after opening and dilution, or reconstitution 
of a solutions and suspensions. 
 
 
I -10  Val idation of the Analyt ical Procedure
(1 6 ,  2 1 )  
 
 
The objective of validation of an analytical procedure is to 
demonstrate that it is suitable for its intended purpose. The analytical 
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procedure refers to the way of performing the analysis. It should 
describe in detail the steps necessary to perform each analytical test. 
This may include but is not limited to: the sample, the reference 
standard and the reagents preparations, use of the apparatus, 
generation of the calibration curve, use of the formulae for the 
calculation, etc. 
 
Validation of the analytical procedures is directed to the four most 
common types of analytical procedures: 
1- Identification tests. 
2- Quantitative tests for impurities’ content. 
3- Limit tests for the control of impurities. 
4- Quantitative tests of the active substance or other selected 
component(s) in samples of substance or medicinal product. 
 
The assay represents a quantitative measurement of the active or 
other selected components. Following are the typical validation 
characteristics which should be considered: 
 
I-10-1 Accuracy 
 
 
The accuracy of an analytical procedure expresses the 
closeness of agreement between the value which is accepted 
either as a conventional true value or an accepted reference 
value and the value found. This is sometimes termed trueness. 
 
I-10-2 Precision 
 
 
The precision of an analytical procedure expresses the 
closeness of agreement (degree of scatter) between a series of 
measurements obtained from multiple sampling of the same 
homogeneous sample under the prescribed conditions. 
Precision may be considered at three levels: repeatability, 
intermediate precision and reproducibility. Precision should be 
investigated using homogeneous, authentic samples. However, 
if it is not possible to obtain a homogeneous sample it may be 
investigated using artificially prepared samples or a sample 
solution. The precision of an analytical procedure is usually 
expressed as the variance, standard deviation or coefficient of 
variation of a series of measurements. 
 
I-10-3 Specificity (selectivity) 
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Specificity is the ability to assess unequivocally the analyte in 
the presence of components which may be expected to be 
present. Typically these might include impurities, degradants, 
matrix, etc. Lack of specificity of an individual analytical 
procedure may be compensated by other supporting analytical 
procedure(s). 
 
I-10-4 Linearity 
 
 
The linearity of an analytical procedure is its ability (within a 
given range) to obtain test results which are directly 
proportional to the concentration (amount) of analyte in the 
sample. 
 
I-10-5 Range 
 
 
The range of an analytical procedure is the interval between the 
upper and lower concentration (amounts) of analyte in the 
sample (including these concentrations) for which it has been 
demonstrated that the analytical procedure has a suitable level 
of precision, accuracy and linearity. 
 
I-10-6 Robustness 
 
 
The robustness of an analytical procedure is a measure of its 
capacity to remain unaffected by small, but deliberate variations 
in method parameters and provides an indication of its reliability 
during normal usage. 
 
 
Furthermore revalidation may be necessary in the following 
circumstances: 
 
1- changes in the synthesis of the active substance; 
2- changes in the composition of the medicinal product; 
3- changes in the analytical procedure. 
 
The degree of revalidation required depends on the nature of the 
changes. Certain other changes may require validation as well. 
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I -11  Bioequivalence Study
( 3 ,11 ,18 ,1 9 )
 
 
 
Bioavailability is defined as a measure, relative to some standard, of 
the rate and amount of drug which reaches the systemic circulation 
unchanged following the administration of a suitable dosage form.  
 
The gastrointestinal barrier is structurally a complex assemblage of 
lipids, proteins, lipoproteins and polysaccharides. Lipid-soluble 
substances penetrate the gastrointestinal boundary through passive 
diffusion by dissolving in the lipid like phase. Polar substances also 
penetrate the gastrointestinal boundary through passive diffusion if 
they are small enough to filter through microscopic pores in the 
membrane or the spaces between cells.  
 
 
Passive diffusion can be described by Fick’s law:  
  
dm/dt = D A K1 Cg / h  
 
Where:  
dm/dt: Rate of appearance of drug in the blood at the site of 
absorption. 
D:   Effective diffusion coefficient of the drug in GI membrane, 
A:   Surface area of GI membrane, 
K1: Apparent partition coefficient of the drug between the GI 
membrane and the GI fluid 
Cg:  The concentration of drug in solution in the gastrointestinal 
fluid in the site of absorption. 
h:   The thickness of GI membrane. 
 
Fluconazole is soluble in 0.1 N HCl, has lipophilic properties and has 
90 % bioavailability versus the IV. Thus, a passive absorption is most 
likely occurs. 
 
Few lipid-insoluble drugs are absorbed by Active Transport process. 
A carrier, which may be an enzyme or some other component of the 
cell membrane is responsible for effecting the transfer of drug. Active 
transport is a process whereby materials can be transported against 
a concentration gradient across a cell membrane. Therefore, active 
transport is an energy consuming process.  
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Facilitated diffusion or transport is also a carrier-mediated transport 
system which differs from active transport in that it cannot transport a 
substance against a concentration gradient of the substance. 
Therefore it does not require an energy input, but it does require a 
concentration gradient for its driving force.  
 
In-Vivo bioequivalence is made to assure the similarity of the 
bioavailability between the developed formula and the original drug. 
This is done on 24 healthy volunteers according to FDA regulations. 
They are chosen all within the normal weight range. They are 
examined clinically for normal hematological value, renal and hepatic 
function values. Exclusion criteria included extreme weight ranges, 
anemia, liver or renal dysfunction, parasitic and other disease or 
conditions that is judged to affect the absorption, distribution and 
elimination of the drug substance. 
 
 
 
The assessment of bioequivalence between the test and the 
reference product is based on the ratios of the mean pharmacokinetic 
parameters (Cmax, tmax, AUC 0∞) using ANOVA. Bioequivalence is 
concluded if either tail probability did not exceed the 90% confidence 
limit and was completely contained in the 0.80 – 1.25 range. 
 
 
 
I -12  Biological  evaluation of anti fungal  and 
antibacterial  activi ty 
(3 ,7 ,8 )
  
 
 
I-12-1 Antibacterial activity 
 
 
To evaluate the antibacterial activity of a drug substance, the 
measurement of the minimum inhibitory concentration against 
particular test organism is performed. MIC is the lowest 
concentration of the drug substance found to inhibit the growth of 
the test organism. MIC is an absolute value and is not a 
comparison between standard and a sample. It is usually 
expressed in g / ml.  Other experimental details should be 
stated with the result such as the inoculum concentration and the 
culture medium. Fluconazole is an antifungal agent and its 
antibacterial effect will be evaluated against several pathogenic 
bacterial strains. British and US pharmacopoeias evaluate the 
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product cleanness by a specific total bacterial count and the 
absence of four pathogenic microorganisms: Salmonella, 
Staphylococcus Aureus, Pseudomonas Aeruginosa and 
Escherishia Coli. These microorganisms will be used in 
evaluation of the antibacterial effect of Fluconazole. To calculate 
the inoculum concentration used in the test, a plate count method 
is used. The method is done by preparing several dilutions of the 
inoculum solution used and spread a determined volume from it 
on a specific agar medium, and then incubate at 35-37 C for 24-
48 hours. Each microorganism grows to form a colony. By 
calculating the number of colonies in a certain plate, and 
multiplying by the dilution factor of that plate, the original 
bacterial concentration is calculated.  
 
 
I-12-2 Biological Assay comparison 
 
 
There is no official monograph for calculating the biological assay 
potency of an antifungal. The available biological tests for the 
assay are done for antibiotics. The test compares the potency of 
a test sample with a reference one. There are two official 
methods for calculating the potency: 
 
a- Cylinder Plate method 
The test organism is inoculated in a specific agar medium. 
The agar is poured in a specific sterile plate. Wells or 
cylinders are placed on the surface of the plate at a 
specified distance. A specific volume of the antibacterial 
solution of known concentration is placed inside the well or 
cylinder. The solution diffuses through the agar forming 
zones, inhibiting the growth of the bacteria at this zone. 
The diameter of the zone depends on the concentration of 
the antibacterial used. A standard is prepared at the same 
concentrations and the zone diameters are compared 
together and calculation is done for the potency of the test 
sample. 
    
b- Turbidimetric method 
The test organism is inoculated in broth medium placed in 
sterile tubes. Different concentrations of the test solution 
are placed in the tubes. The transmittance of each tube is 
measured and compared to standard. The transmittance 
measure depends on the concentration of the antibacterial. 
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The plate method is preferred as standards and samples are 
found on the same plate, thus have the same conditions. For 
development of a method for Fluconazole, it is important to 
choose the suitable agar medium and test microorganism. Once 
a method of a biological assay is developed, Fluconazole tablet 
is evaluated using the original brand as the standard.  The 
potency ratio may be calculated based on two point 
concentration assay using the following formula: 
 
(UH + UL) – ( SH + SL) 
Log X = LDR x              …….(3) 
 (SH - SL) + ( UH - UL) 
 
Where  
X = the potency ratio 
LDR = the logarithm of the dose ratio (ratio of the concentration 
of standard solutions) 
UH = zone diameter for the higher concentration of the sample 
UL = zone diameter for the lower concentration of the sample  
SH = zone diameter for the higher concentration of the standard 
SL = zone diameter for the lower concentration of the standard  
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PART II: EXPERIMENTAL 
 
 
I I -1 Speci f ication and Test Method for the Active 
Substance ―Fluconazole‖  
 
II-1-1 Specification (as per manufacturer, year 2002) 
 
 
Empirical formula C13H12F2N6O 
 Molecular weight 306.3 
Description  Take 2 grams of the material and distribute it on 
a glass plate. Record the observations 
Melting range  Charge the capillary glass rod of the melting 
range tester with the material to be analyzed. 
Record the temperature on which the material 
melts 
Odor Take 2 grams of the material and distribute it on 
a glass plate. Smell the material from  a suitable 
distance. Record the odor. 
Solubility  slightly soluble in water, 5% w/v solution in 
methanol is clear.  
Loss on Drying at 105 ºC Dry about 5 grams of the material at 105 C for 4 
hours using the heat balance. Record  the loss 
percentage. 
Residue on Ignition Weight 1.0 gm of the substance in a suitable 
crucible that previously has been ignited, 
cooled and weighed. Heat, gently at first until 
the substance is thoroughly charred, cool, 
moisten the residue with 1 ml of sulfuric acid, 
heat gently until white fumes no longer are 
evolved, and ignite at 800 ± 25°C, until the 
carbon is consumed . 
Cool in desiccators, weigh, and calculate the 
percentage of the residue. If the amount of the 
residue so obtained exceeds the limit 
specified , again moisten the residue with 1 N 
sulfuric acid, heat and ignite as before , and 
again calculate the percentage of the residue . 
Unless otherwise specified, continue ignition 
until constant weight is attained or until the 
percentage of the residue complies with the 
limits. 
Heavy Metals Standard Preparation: 
Into a 50-ml color-comparison tube pipet 1 ml of 
standard lead solution (10 μg of Pb), and dilute 
with water to 25 ml. Adjust with 1 N acetic acid 
or 6 N hydrochloric acid to pH of 3.5, dilute with 
water to 100 ml, and mix. 
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Test Preparation: 
Transfer 1.0 gm of the substance to suitable 
crucible ,add sufficient sulfuric acid to wet the 
substance,  and carefully ignite at low 
temperature until thoroughly charred, add to the 
carbonized mass 2 ml of nitric acid and 5 drops 
of sulfuric acid, and heat cautiously until white 
foam no longer are evolved. Ignite, preferably in 
a muffle furnace, at 500°C to 600°C, until the 
carbon is completely burned off.. Cool, add 4 ml 
of 6 N hydrochloric acid, cover, digest on a 
steam bath for 15 minutes, uncover, and slowly 
evaporate on steam bath to dryness. Moisten 
the residue with 1 drop of hydrochloric acid, add 
10 ml of hot water, and digest for 2 minutes. 
Add 6 N ammonium hydroxide dropwise, until 
the solution is just alkaline to litmus paper, 
dilute with water to 25 ml, and adjust with 1 N 
acetic acid to pH between 3.0 and 4.0, using 
short-range pH indicator paper as external 
indicator .Filter if necessary, rinse the crucible 
and filter with 10 ml of water, combine the 
filtrate and rinsing in 50-ml color-comparison 
tube dilute with water to 40 ml,  then mix. 
 
Procedure: 
To each of the tubes containing standard 
preparation and test preparation , add 2ml of pH 
3.5 acetate buffer, then add 1.2 ml of 
thioacetamide-glycerin base TS, dilute with 
water to 50 ml, mix, allow to stand for 2 
minutes, and view downward over a white 
surface, the color of the solution from the test 
preparation is not darker than that of the 
solution from the standard preparation. 
Related Substances by 
HPLC 
Sum of impurities not more than 1.0% 
Particle size: 100% < 180 µm 
Bulk Density: 
Untapped 
 
0.25 to 0.45  gm / ml 
Tapped 0.35 to 0.55  gm / ml 
 
 
II-1-2 Assay  
 
a- Instrument 
Merck-Hitachi HPLC systems consisting of an 
autosampler model L-7200, a pump model L-7100 and a 
diode array detector model L-7450A, 
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b- Mobile Phase 
Mix 45% water and 55% Methanol.  
c- Stationary Phase 
LiCrospher RP-18 e, 5 m, 250x 4mm.  
 
d- Flow Rate 
0.5 ml/minute. 
 
e- UV Wavelength 
261 nm. 
 
f- Standard Preparation: 
Dissolve 150 mg Fluconazole reference standard 
accurately weighed in a 100-ml volumetric flask, add 70 
ml of mobile phase, shake and sonicate for 5 minutes, 
and complete the volume to the mark using the mobile 
phase. Dilute 5 ml in 50 ml mobile phase. 
  
g- Sample Solution Preparation: 
Dissolve 150 mg Fluconazole sample accurately 
weighed in a 100-ml volumetric flask, add 70 ml of 
mobile phase, shake and sonicate for 5 minutes, and 
complete the volume to the mark using the mobile 
phase. Dilute 5 ml in 50 ml mobile phase 
 
 
h- Procedure 
Let the mobile phase running until reaching a stable 
state of equilibrium. After filtration using a membrane 
filter of (0.20 m), inject separately equal volumes (20 
L) of the prepared solutions triplicate as follows 
(Standard, Sample, Standard, Sample, Standard and 
Sample) into the chromatograph. 
 
 
i- Calculation 
 
    Sample peak area 
% Fluconazole  =                     100  
    Standard peak area 
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I I -2 Speci f ication and Test Method for the Final 
Product Fluconazole Tablet  
 
 
II-2-1 Specification 
 
 
a- Shape: Triangular tablets 
 
b- Unit Weight (None Coated):  251.0 mg   12.5 mg. 
 
c- Color: Beige color. 
 
d- Odor: Odorless. 
 
e- Diameter:  9.0  0.5 mm. 
 
f- Hardness:  Min. 4.0 K. 
 
g- Friability:  Max. 1.0% (100 rounds). 
 
h- Description of Filling Material:  a sachet made from Aluminum 
Foil (0.02 mm) on one side and colorless PVC (0.25 mm) on 
the other side. 
 
 
II-2-2 Assay 
 
 
a- Instrument 
Merck-Hitachi HPLC systems consisting of an autosampler 
model L-7200, a pump model L-7100 and a diode array 
detector model L-7450A, 
 
b- Mobile Phase 
Mix 45% water and 55% Methanol.  
c- Stationary Phase 
LiCrospher RP-18 e, 5 m, 250x 4mm.  
 
d- Flow Rate 
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0.5 ml/minute. 
 
e- UV Wavelength 
261 nm. 
 
f- Standard Preparation: 
Dissolve 150 mg Fluconazole reference standard accurately 
weighed in a 100-ml volumetric flask, add 70 ml of mobile 
phase , shake and sonicate for 5 minutes, and complete the 
volume to the mark using the mobile phase. Dilute 5 ml in 50 ml 
mobile phase. 
 
g- Sample Solution Preparation: 
 
Weigh not less than ten tablets, determine the average weight, 
and powder them. Weigh in powder exactly the average weight 
of one and a half tablet and dissolve it in a 100-ml volumetric 
flask, add 70 ml of mobile phase , shake and sonicate for 5 
minutes and complete the volume to the mark using the mobile 
phase. Dilute 5 ml in 50 ml mobile phase. 
 
h- Procedure 
Let the mobile phase running until reaching a stable state of 
equilibrium. After filtration using a membrane filter of (0.20 m), 
inject separately equal volumes (20 L) of the prepared 
solutions twice as follows (Standard, Sample, Standard and 
Sample) into the chromatograph. 
 
 
i- Calculation 
 
    Sample peak area 
Fluconazole  =                     100%  
    Standard peak area 
 
 
II-2-3- Dissolution 
 
 
a- Medium: 900 ml 0.1N HCl. 
 
b- Apparatus: paddle, 50 round/min 
 
28 
c- Time: 45 min 
 
d- Temperature: 37 ± 1 Cº 
 
e- Standard preparation:  
Transfer the weight of 11.1 mg of Fluconazole RS accurately 
weighed to 100 ml volumetric flask, add 15 ml of methanol, 
shake and sonicate for 5 min, add 70 ml of dissolution 
medium, sonicate for another 5 minutes, wait until cooling, 
then complete to the volume using dissolution medium. 
 
f- Sample preparation:  
After the dissolution time is over, directly and as soon as 
possible take and filter the needed samples from each 
dissolution vessels. 
 
g-  Procedure:    
HPLC, the same settings as directed in the assay test. 
 
h- Limits: 
Not less than 80% of the active ingredient or ingredients 
dissolves within 45 minutes. If one unit fails to meet this 
requirement, a retest may be carried out using the same 
number of units; all units in the retest must comply. 
 
II-2-4- Other tests: 
 
a. Content uniformity 
 
Assay 10 units individually as directed in the assay. 
 
Limit:  
If the average of the limit specified in the potency definition in 
the individual monograph is 100% or less: proceed as follows: 
the amount of the active ingredient in each 10 dosage lies within 
the range of 85.0 % to 115.0 % of the labeled claim and the 
relative standard deviation is ≤ 6.0%. If one dosage is out side 
the range 85.0 % to 115.0 % of the labeled claim and no unit is 
outside the (75.0% - 125.0%) or the RSD is greater than 6.0% or 
both, test additional 20 unit, the requirement are met if not more 
than 1 unit of the 30 units is outside the range of 85.0%to 
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115.0% of the labeled claim, and no unit is outside the range of 
75.0% to 125.0% of the labeled claim and the RSD of the 30 
dosage unite does not exceed 7.8%. 
 
 
b. Hardness:  
 
Take 10 tablets randomly and measure the hardness of each 
tablet. 
 
Limit: Each tablet must lie in the range of Min. 4.0 K 
 
c. Friability:  
 
Take the weight (initial weight) of 20 tablets and place them in 
the friability device and rotate 100 rounds.  Reweigh (final 
weight) the tablets and calculate the friability ratio. 
 
Calculation: 
    initial weight - final weight  
Friability ratio =------------------------------------------------X100  
initial weight 
 
Limit: maximum 1.0% 
 
 
II-2-5 Physical tests:  
 
a. Purity:  
Examine the material visually or by using a microscope 
for any strange bodies or black spots. 
 
Limits:  No strange matter should be found in the 
powder. 
 
b. Odor: 
Examine the material for the powder odor, compare its 
odor with a reference standard. 
 
Limits: The granule odor should be identical to the 
reference standard. 
 
c. Chipping and capping: 
Examine the surface of tablets visually. 
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Limits:  No chipping or capping should be found on the 
tablets surface. 
 
 
I I -3 Val idat ion of the Test Method  
 
II-3-1 Selectivity: 
 
The following solutions were analyzed under the same conditions 
in order to determine that there is no interference between the 
active material peak and the other peaks: 
 
a. Standard Solution Preparation: 
 
75 mg Fluconazole accurately weighed was transferred to 50-
ml volumetric flask, 40 ml of mobile phase was added, 
sonicate for 5 minutes, allow to cool to room temperature, 
complete the volume to the mark using the same solvent. 
Pipette 5.0 ml of the prepared solution into a 50-ml volumetric 
flask and complete the volume to the mark using mobile 
phase The final dilution concentration is 15.0 % (mg/ml)of 
Fluconazole . 
 
b. Sample Solution Preparation: 
 
Transfer in powder exactly the weight of one and half tablet 
(375 mg) to a 100-ml volumetric flask, add 70 ml of the mobile 
phase, sonicate for 15 minutes and allow to cool to room 
temperature. Complete the volume to the mark using the 
same solvent. Allow any insoluble matter to settle, then 
transfer 5  ml of this solution to 50ml- volumetric flask, and 
complete to the volume using the same solvent. The final 
dilution concentration is  15.0 % (mg/ml)of Fluconazole . 
 
c. Placebo Solution Preparation: 
 
Transfer about 225 mg of a placebo Dican 100 tablet to 100-
ml volumetric flask, add 70 ml of the mobile phase, sonicate 
for 15 minutes and cool to room temperature. Complete the 
volume to the mark using the same solvent [Solution A]. 
Pipette 5.0 ml of the prepared solution into a 50-ml volumetric 
flask and complete the volume to the mark using the mobile 
phase 
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The selectivity is also made for solution prepared under stress 
conditions. Solution samples of Fluconazole in the following 
solvents are prepared: 5N NaOH, 5N HCl, 30 % H2O2 and in 
water. The samples are kept for 48 hours. The water sample 
is boiled for 5 minutes and kept at 60
◦
C for the same period. 
The assay, purity check are calculated. A check is also made 
for any peaks in the chromatograms. 
 
II-3-2 Accuracy and Precision: 
 
a. Evaluate the Accuracy and the Precision of the method 
on three trials (one trial per a day). Five sample solutions 
are prepared using a different trial for each day. 
b. Sample and Standard Solutions: Prepare the sample and 
the standard solutions as directed under Selectivity. 
c. Use the same batch of Fluconazole for the three trials. 
 
III-3-3 Linearity: 
 
a. Prepare five concentrations: 60%, 80%, 100%, 120%, 
and 140% of the final dilution concentration.  
b. Use the same batch of the active material for all the 
solutions. 
c. Prepare [Solution B] by dissolving 150 mg of Fluconazole 
in 100 ml mobile phase. 
d. Prepare the concentration indicated in the following table: 
 
Table II-1: Concentration preparation for Linearity 
Concentration 
(%)  
[Solution A] 
(ml) 
[Solution B] 
(ml) 
Mobile Phase 
(ml) 
60 5 3.0 42 
80 5 4.0 41 
100 5 5.0 40 
120 5 6.0 39 
140 5 7.0 38 
     
II-3-4 Robustness: 
 
Prepare a sample and a standard solutions as directed under 
Selectivity, and analyze according to the following criteria: 
 
a.  Two Different Analysts: 
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Each analyst must prepare the sample and the standard 
solutions to be analyzed using the same manner and 
under the same conditions. Each analyst must use the 
same prepared trial.  
 
b.  Two Different Instruments: 
Use each of the Hitachi, (RI001) and the Hitachi, (RI002) 
HPLC systems.  
 
c.  Different elapsed assay times: 
 
Preparation Time: 
Analyze the same sample solution after 10 minutes and 
after 4 hours of preparing the sample solution. 
Sonicating Time: 
 
Sonicate each sample solution according to the following 
criteria: 
Sample 1: sonicate for 10 minutes. 
Sample 2: sonicate for 15 minutes. 
Sample 3: sonicate for 20 minutes 
 
d.  Different columns: 
 
Analyze the same sample solution using two different 
columns, which is of the same type and dimensions, 
(LiCrospher 100 RP-18, 5 μm, 250x4 mm). 
 
II-3-5 Acceptance Criteria 
 
Table II-2: Acceptance criteria for validation 
Parameter Statistical Measure Limits 
 
Selectivity None 
No interference between the 
active material peak and 
other peaks  
Accuracy Percent of Recovery 98.00 - 102.00 
Precision Coefficient of Variation  Maximum  1.50 
Linearity Correlation Coefficient 
Y-Intercept 
Minimum 0.99980 
 2.0 % of  the average area 
Ruggedness Coefficient of Variation  Maximum  1.50 
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I I -4 Formulation 
 
 
II-4-1 Choice of Excipients 
 
 
As a direct compression formula, the following excipients were 
selected for the trials: 
 
Table II-3: Excipients used for trials in Fluconazole tablet formulation 
 Material Function 
1 Fluconazole Active substance 
2 Avicel 102 Filler and Binder 
3 Ac-Di-Sol Disintegrant 
4 Lactose spray dried Filler 
5 Lactose monohydrate Filler 
6 Aerosil Glidant 
7 Mg Stearate Lubricant 
8 Yellow iron oxide Coloring Agent 
 
All of the above materials are used for direct compression 
formulations.  
 
II-4-2 Equipments and Machines 
Trials are done on small batches (1 Kg).  Mixing is done 
manually in PE bags and a single punch tableting machine is 
used. A pilot batch (30 Kg) is done for the best formula using 
the drum mixer and a rotary 16 punches tableting machine.  
 
Drum mixer (50 Kg capacity) 
Screen mesh 325 µm (mesh # 58) 
Tableting machine, single punch. 
Tableting machine, 16 punches.  
Blistering machine. 
 
II-4-3 Trials to be done 
The trials are tested for the following parameters: 
Flowability 
Hardness 
Disintegration time 
Weight variation 
Color homogeneity (when color is used) 
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a- Effect of filler type (Lactose monohydrate vs Lactose spray 
dried). 
 
Table II-4: Composition of trials #1 vs # 2 
  Trial # 1 Trial # 2 
Material  mg % mg % 
Fluconazole 100 40% 100 40% 
Avicel 102 62.5 25% 62.5 25% 
Lactose 77.5 31% ****** ****** 
Lactose Spray 
Dried ****** ****** 77.5 31% 
Aerosil 2.5 1% 2.5 1% 
Mg-Stearate 2.5 1% 2.5 1% 
Ac-di-sol 5.0 2% 5.0 2% 
 Total weight 250   250   
 
 
b- Effect of binder concentration (Avicel 102) on the hardness 
and disintegration: 
 
 
Table II-5: Composition of trials #2 vs # 3 
  Trial # 2 Trial # 3 
Material   mg % mg % 
Fluconazole 100 40% 100.0 40% 
Avicel 102 62.5 25% 45.0 18% 
Lactose Spray 
Dried 77.5 31% 95.0 38% 
Aerosil 2.5 1% 2.5 1% 
Mg-Stearate 2.5 1% 2.5 1% 
Ac-di-sol 5.0 2% 5.0 2% 
 Total weight 250   250   
 
c- Effect of the presence of the disintegrant (Ac-Di-Sol) in the 
formula: 
 
Table II-6: Composition of trials #3 vs # 7 
  Trial # 2 Trial # 7 
Material   mg % mg % 
Fluconazole 100 40% 100.0 40% 
Avicel 102 62.5 25% 62.5 25% 
Lactose Spray 
Dried 77.5 31% 82.5 33% 
Aerosil 2.5 1% 2.5 1% 
Mg-Stearate 2.5 1% 2.5 1% 
Ac-di-sol 5.0 2% 0 0 
 Total weight 250   250   
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d- Effect of low concentration of the disintegrant (Ac-Di-Sol) on 
the disintegration time: 
 
 
Table II-7: Composition of trials #3 vs # 4 
  Trial # 3 Trial # 4 
Material   mg % mg % 
Fluconazole 100 40% 100.0 40% 
Avicel 102 62.5 25% 62.5 25% 
Lactose Spray 
Dried 77.5 31% 80.0 32% 
Aerosil 2.5 1% 2.5 1% 
Mg-Stearate 2.5 1% 2.5 1% 
Ac-di-sol 5.0 2% 2.5 1% 
 Total weight 250   250   
 
 
e- Effect of the coloring material Yellow iron oxide: 
 
The color is mixed with the other excipients in the first stage. 
  
Table II-8: Composition of trial #5 
  Trial # 5 
 Material  mg % 
Fluconazole 100 40% 
Avicel 102 62.5 25% 
Lactose Spray 
Dried 76.2 30.5% 
Aerosil 2.5 1% 
Mg-Stearate 2.5 1% 
Ac-di-sol 5.0 2% 
Yellow Iron Oxide 1.3 0.5% 
 Total weight 250   
 
 
f- Effect of the hardness on disintegration time: 
 
Five hardness ranges to be tested on trial # 2: 
 
Table II-9: Different hardness ranges to be tested 
Range Limits 
A 4-6 
B 6-8 
C 8-10 
D 10-12 
E 12-14 
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All formulas to be prepared by the following direct compression 
method (Figure II-1): 
 
 
 
Figure II-1: Step by Step production scheme 
Screen 
325 µm 
All materials except 
the Magnesium 
Stearate 
Mixing for 15 
minutes 
Screen 
325 µm 
Mg Stearate 
Mixing for  
5 minutes 
Compressing 
Drum 
Mixer 
Drum 
Mixer 
Blistering 
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I I -5 Dissolut ion Profi le:  
 
 
Six tablets of the trial batch to be tested and six capsules of the 
original brand (Trican by Pfizer) to be compared using the 
dissolution test. The samples of each trial is taken every 10, 15, 
20, 25, 35 and 45 minutes. The samples are injected in the HPLC 
system (using the dissolution test method). A comparative graphs 
are drawn.  The comparison of the dissolution profile is calculated 
by the following formulas: 
 
F1 = {[Σn t=1IRt-TtI] / [Σ
n t=1Rt]} x 100 
 
F2 = 50 log {[1+(1/n) Σn t=1(Rt-Tt)
2]-0.5  x 100} 
 
 
Where: 
F1: The percentage difference between the two profiles at each 
sampling point. 
F2: The similarity factor corresponds to the similarity measurement 
between two curves 
n:   number of samples 
Rt: The percentage dissolved of the original brand at time t. 
Tt: The percentage dissolved of the trial formulation at time t. 
 
Limits:  
F1 = 0 - 15 
F2=50 - 100 
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I I -6 Accelerated Stabi l i ty Protocol on the f inal  
product:  
 
 
II-6-1 Effect of accelerated conditions: 
 
a. Composition: 
Each tablet contains 100 mg Fluconazole. 
 
b. Formula: 
 
Table II-10: Formula used in the accelerated stability testing 
RM g % 
Fluconazole 400.00 40.0 
Avicel 102 248.00 24.8 
Lactose Spray Dried 310.00 31.0 
Aerosil 10.00 1.0 
Mg-Stearate 10.00 1.0 
Ac-di-sol 20.00 2.0 
Yellow Iorn Oxide 2.00 0.2 
Total 1000.00 100.0 
 
 
c. Batch Numbers: 
      R3G02 (pilot batch 30 Kg)  
      R4G02 (lab batch 1 Kg) 
      R5G02 (lab batch 1 Kg) 
  
d. Packing: 
Blisters of aluminum (0.02 mm) and colorless PVC (0.25 
mm). 
 
e. Storage date: 
 8/08/2002. 
 
f. Storage Period: 
Six months. 
 
g.  Testing intervals:  
Initial, 1 month, 3 months and 6 months. 
 
h. Storage conditions: 
Temperature 40 ºC, humidity 75 % R.H. 
Temperature 30 ºC, humidity 60 % RH 
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i. No. Of sample: 
     100 Tablets for each condition. 30 tablet for each test interval 
(not including initial) + 10 additional. 
 
j. Acceptance criteria: 
 
Table II-10: Acceptance criteria for accelerated stability testing 
Testing parameters Limits 
Identification (RT min) Complies 
Assay (90.0-110.0)% 
Dissolution 
Min 80.0% in 45 
minutes 
Appearance tests Beige 
Hardness Min 4.0 K 
Odor Odorless 
 
 
 
II-6-2 Effect of light on final products: 
 
1. Batch Number: 
      R1G02 
        
2. Packing: 
Blisters of aluminum (0.02 mm) and colorless PVC (0.25 
mm). 
 
3. Storage date: 
 8/08/2002. 
 
4. Period of storage: 
7 months. 
 
5. Storage condition: 
The blisters are exposed to light (day light during the day and 
Neon light during night) at room temperature. 
                            
6. No. Of sample: 
     30 Tablets for each testing interval. 
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7. Acceptance criteria: 
 
Table II-11: Acceptance criteria for long term stability testing 
Testing parameters Limits 
Identification (RT min) Complies 
Assay (90.0-110.0)% 
Dissolution Min 80.0% 
Appearance tests Beige 
Hardness Min 4.0 K 
Odor Odorless 
 
 
I I -7 Bioequivalence of the formula ted tablet  
versus the innovator product Di f lucan for Pfizer  
 
 
The formula used for the study is indicated in Table II-10. 
 
The study is done on 24 healthy volunteers. The subjects are asked 
to abstain from taking drugs and alcohol for at least 3 days prior to 
the experiment and throughout the study period. On the night before 
the experiment the volunteers are instructed to fast at least 10 hours 
before drug administration.  
The volunteers are arbitrary divided into two equal groups each of 12 
subjects. The first group was given the Trican capsule by Pfizer and 
the second is given Dican tablet with a crossover after washout 
period of two weeks. Blood samples are collected before and at 0.5, 
1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 96 hours post 
administration. Analysis of plasma sample concentrations is done by 
means of a validated HPLC assay method.  
 
Statistical analysis is performed using Minitab Statistical Package 
version 13 on IBM PC. The assessment of bioequivalence between 
the test and the reference product is based on the ratios of the mean 
pharmacokinetic parameters (Cmax, tmax, AUC 0∞) using ANOVA. 
Bioequivalence was concluded if either tail probability did not exceed 
the 90% confidence limit and was completely contained in the 0.80 – 
1.25 range. 
 
Limits of acceptance are as follows: 
 
AUC 0∞ : 80 to 125% 
Cmax       : 80 to 125% 
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I I -8 Microbial  comparison between the Dican and 
Trican (Dif lucan) for Pf izer.  
 
 
II-8-1 Method used: Plate method 
 
II-8-2 Test organism: Candida Albicans 
 
II-8-3 Materials and equipment’s 
 
Petri dishes: plastic Petri dishes having 200 mm diameter 
and 10 mm height. 
Autoclave 
Incubator 
Laminar flow 
 
 
II-8-4 Media and diluent 
 
 
a- Buffer No. 10, 0.2  M,  pH  10.5: Dissolve 35.0 g of dibasic 
potassium phosphate in 1000 ml of water, and add 2 ml of 
10 N potassium hydroxide. Adjust the pH with 18 N 
phosphoric acid or 10 N potassium hydroxide to 10.5 ± 
0.1. 
 
b- Antibiotic media No. 3 with agar. 
Composition per 1 liter: 
Beef extract 1.50 g 
Yeast extract   1.50 g 
Peptone           5.00 g 
Dextrose           1.00 g 
NaCl                 3.50 g 
Dipotassium hydrogen Phosphate  3.68 g 
Potassium Dihydrogen Phosphate 1.32 g 
Agar                  1.32 g 
 
Final pH = 7.0  
 
c- Tryptic Soy Broth (TSB). 
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Composition per 1 liter: 
Peptone from Caseine 17.00 g 
Peptone from Soy meal   3.00 g 
D (+) - Glucose           2.50 g 
NaCl           5.00 g 
Dipotassium hydrogen Phosphate 2.50 g 
 
 
II-8-5 Preparation of inoculum 
 
 
a- From the stock inoculum, inoculate a loop full of the 
organism in about 25 ml of (TSB). Stir well using the 
vortex. 
b- Incubate at T = 32-35 °C for 24 hours 
c- Measure the transmittance at = 580 nm 
f- Adjust transmittance to 25% against the TSB as the blank. 
Use TSB for dilution if necessary. 
 
II-8-6 Standard preparation 
 
 
a. Prepare the stock solution by dissolving (use sonication) 
Trican 150 mg capsule in 150 ml buffer solution # 10 
(pH=10.5).  
b. Pipette 10 ml of this stock solution into a 50 ml volumetric 
flask and fill up to volume with buffer solution (SH). 
c. Dilute 15 ml of this solution with 30 ml with buffer solution. 
(SL). 
 
II-8-7 Sample preparation 
 
 
a. Weigh not less than ten tablets, determine the average 
weight, and powder them. Prepare the stock solution by 
dissolving (use sonication) the average of 1 tablet 
accurately weighed in buffer solution # 10 (pH=10.5) in 
100-ml volumetric flask and fill up to volume with the 
same solvent.  
b. Pipette10 ml of this stock solution into a 50 ml volumetric 
flask and fill up to volume with buffer solution (UH). 
c. Dilute 15 ml of this solution with 30 ml with buffer solution. 
(UL). 
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II-8-8 Procedure 
 
 
a. Keep the medium in the water bath at 45-50 degree until 
use. 
b. Prepare the first layer by placing 13 ml of the antibiotic 
medium in each plate and wait till solidification.  
c. 1 ml of the 25 % bacterial suspension is added to 50 ml of 
the antibiotic medium prepared. Mix well. 
d. Prepare the second layer by placing 5 ml of the 
inoculated medium, tilt the plate pack and forth to spread 
the media and let it to harden at room temperature 
e. Using a 6 mm SS cylinder tube, make 4 wells in each 
plate. Make sure to make even space at a radius of 2.8 
cm apart. 
f. Cover the plates to avoid contamination. 
g. Fill each well with 75 µl of the prepared dilutions of 
sample and standard as distributed 
h. Incubate the plates at 35-37 °C for 24 hours 
i. Measure the diameter of each zone of inhibition formed to 
the nearest 0.1 mm 
 
 
 
 
II-8-9 Calculations 
 
Use the following equation to calculate the potency ratio: 
 
(UH + UL) – ( SH + SL) 
Log X = LDR x              
 (SH - SL) + ( UH - UL) 
 
 
 
I I -9 Anti  Microbial Activi ty of Fluconazole.  
 
 
II-9-1 Materials 
 
 
a. Sterile TSB. 
b. Sterile Saline (0.9 % NaCl). 
c. Tryptic Soy Agar 
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Composition per 1 liter: 
Peptone from Caseine 15.00 g 
Peptone from Soy meal   5.00 g 
NaCl           5.00 g 
Agar 15.00 g 
d. Buffer No. 3, 0.1  M,  pH  8.0 — Dissolve 16.73 g of 
dibasic potassium phosphate and 0.523 g of monobasic 
potassium phosphate in 1000 mL of water.  djust the pH 
with 18 N phosphoric acid or 10 N potassium hydroxide to 
8.0 ± 0.1. 
e. Buffer No. 10 as described in II-8-4. 
 
II-9-2 Test Organisms: 
 
 
a. Salmonella  
b. Staphylococcus Aureus 
c. Pseudomonas Aeruginosa and  
d. Escherishia Coli 
 
II-9-3 Preparation of the Test Organism 
 
 
a. Prepare a fresh broth of the tested organism by adding a 
loop full from the organism in 25ml of sterile TSB. Stir well 
using the vortex. 
b. Incubate for 24h at T = 32-35 °C. 
c. Take 10 μl of this incubated organism and dilute in 20 ml 
0.9 % saline. 
 
 
II-9-4 Preparation of the antimicrobial chemical dilutions 
 
 
a. Prepare 10 tubes, each have 3 ml of sterile TSB. 
b. Prepare 1mg/ml concentration of the antimicrobial 
chemical by dissolving 100 mg of Fluconazole in 100 ml 
Buffer number 10 described in II-8-4. 
c. Transfer 3 ml of the 1mg/ml concentration of the 
antimicrobial chemical to the first tube to have a 
concentration of 500 μg/ml.  
d. Transfer 3 ml  from  the first tube to the second tube to 
have a concentration of 250 μg/ml  and repeat till reaches 
the tube number 10. 
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e. Take 50 μl of the final concentration of the tested 
organism that was prepared in step II-9-2 and add it to 
each of the 10 tubes (containing 3ml of sterile TSB and 3 
ml of the antimicrobial chemical). 
f. Incubate for 24-48 h at T = 32-35 °C and observe the 
growth of the organism.  
 
II-9-5 Plate count for the inoculum. 
 
 
a. Prepare 3 tubes, each have 9 ml of sterile 0.9 %  Saline. 
b. Transfer 1 ml of the inoculum prepared in II-9-3 in tube #1. 
Mix well. 
c. Transfer 1 ml of the resultant solution from b in tube # 2. 
Mix well. 
d. Transfer 1 ml of the resultant solution from c in tube # 3. 
Mix well. 
e. Prepare 3 plates having 15 ml of Tryptic Soy agar having 
numbers 1, 2 and 3. 
f. Transfer 0.1 ml of each test tube into the  plate having the 
same number. Spread the solution all over the plate using 
a glass rod. 
g. Incubate for 24 hours. 
h. Choose the plate that have 50-200 colonies and count the 
number of colonies. 
i. Calculate the original number of bacteria / ml by multiplying 
with the dilution factor. 
 
 
 
 
II-9-6 Comparison with another antimicrobial. 
 
 
The activity of Fluconazole is compared with the activity of 
Clarithromycin against the Staphylococcus Aureus. The same 
procedure is used with the following modifications:  
 
a- Buffer # 3 pH=8 is used in the preparation of antimicrobial 
solution.  
b- The concentration of Clarithromycin solution used is 0.1 
mg / ml. 
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The activity of Fluconazole and Clarithromycin are compared 
by calculating the effective concentration of each against a 
fixed bacterial concentration.  
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PART III: RESULTS AND DISCUSSION 
 
I I I -1 The Active Substance Speci f ication  
 
 
The active ingredient was analyzed by the manufacturer 
according to the procedure described in II-1. The results are 
summarized in the following table (III-1). All the results were 
according to the specifications. 
 
 
Table III-1: Analysis results for the active substance Fluconazole 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Test Result Specification 
Description  White to off-white 
crystalline powder 
White to off-white 
crystalline powder 
Melting range  138-140 °C   136°C-140°C 
Odor Odorless Odorless or almost 
odorless 
Solubility  5% w/v solution in 
methanol is clear. 
5% w/v solution in 
methanol is clear.  
Loss on Drying at 105 ºC 0.2 % Not more than 0.5% 
w/w 
Residue on Ignition 0.21 % Not more than 0.5% 
w/w 
Heavy Metals < 0.002 % Not more than 0.002% 
w/w 
Iron < 0.002 % Not more than 0.002% 
w/w 
Related Substances by 
HPLC 
0.59 % Sum of impurities not 
more than 1.0% 
Particle size: Complies 100% < 180 µm 
Bulk Density: 
Untapped 
 
0.31 g / ml 
 
0.25 to 0.45 g / ml 
Tapped 0.42 g / ml 0.35 to 0.55 g / ml 
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I I I -2 Formulation summary of results  
 
 
All trials were done with a total weight of 1 Kg 
 
 
III-2-1 Effect of filler type  
 
 
The effect of Lactose monohydrate vs Lactose spray dried was 
studied. The flowability was a lot improved by using the dried form of 
Lactose as indicate in the following table (III-2) 
 
Table III-2: Effect of Lactose spray dries vs Lactose Monohydrate 
Test Trial # 1 Trial # 2 
Flowability Poor Excellent 
Hardness range 4-14 4-14 
Disintegration time Within 2 min. Within 2 min. 
Weight uniformity 
Average wt ± 
5% 
Average wt ± 
5% 
 
 
III-2-2 Effect of binder concentration (Avicel 102)  
 
Two concentrations of Avicel 102 were used (25 % in trial #2 and 18 
% in trial #3). Disintegration was tested on a wide range of hardness 
it was not affected by this variation. In addition, the hardness was 
achieved easily between 4 and 14 K (kilopond) with both 
concentrations. The results are summarized in the following table (III-
3) 
 
Table III-3: Effect of Lactose spray dries vs Lactose Monohydrate 
Test Trial # 2 Trial # 3 
Flowability Excellent Excellent 
Hardness range 4-14 4-14 
Disintegration time Within 2 min. Within 2 min. 
Weight variation 
Average wt ± 
5% 
Average wt ± 
5% 
 
 
III-2-3- Effect of Ac-Di-Sol on disintgration: 
 
 
Two trials were done to study the effect of the disintegrant Ac-Di-Sol 
on disintegration. 2% of Ac-Di-Sol was used in trial #3, while no 
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disintegrant was used at all in trial # 7. There was no complete 
disintegration within 30 minutes in Trial # 7. The disintegration was 
completed within 2 minutes in Trial # 3. The other tests were not 
affected. The results are shown in the following table (III-4). 
 
 
Table III-4: Effect of Ac-Di-Sol on disintegration 
 
 
 
 
 
 
 
 
 
III-2-4- Effect of different concentrations of the disintegrant 
(Ac-Di-Sol) in the formula: 
 
 
Two trials were done to study the effect of the concentration of the 
disintegrant Ac-Di-Sol on disintegration time. 2% of Ac-Di-Sol was 
used in trial #3, while 1% of the  disintegrant was used at all in trial # 
4. A complete disintegration occurred within 15 minutes for the 1%, 
while it is within 2 minutes for the 2%. The results are shown in the 
following table (III-5). 
 
 
Table III-5: Effect of Ac-Di-Sol concentration on disintegration 
 
 
 
 
 
 
 
III-2-5- Effect of the coloring material Yellow iron oxide 
 
 
Trial # 5 contains the coloring agent Yellow Iron Oxide. The tests 
showed no effect of the coloring agent on the flowability, hardness, 
disintegrating time or weight variation. The results are shown in table 
(III-6). 
 
Test Trial # 2 Trial # 7 
Flowability Excellent Excellent 
Hardness range 4-14 4-14 
Disintegration time Within 2 min. 
No complete 
disintegration 
in 30 min. 
Weight variation 
Average wt ± 
5% 
Average wt ± 
5% 
Test Trial # 3 Trial # 4 
Flowability Excellent Excellent 
Hardness range 4-14 4-14 
Disintegration time Within 2 min. 15 minutes 
Weight variation 
Average wt ± 
5% 
Average wt ± 
5% 
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Table III-6: Effect of Yellow Iron Oxide 
Test Trial # 5 
Flowability Excellent 
Hardness range 4-14 
Disintegration time Within 2 min. 
Weight variation Average wt ± 5% 
 
 
 
III-2-6- Effect of hardness on disintegration time  
 
 
The effect of a range of hardness on the disintegration time on 
trial #2. The disintegration was not affected by hardness on the 
range of 4-14 K. The results were summarized in the following 
table (III-7) 
 
Table III-7: Effect of hardness on disintegration time on trial # 2 
Hardness Range (K) Disintegration time 
A (4-6) Within 2 min 
B (6-8) Within 2 min 
C (8-10) Within 2 min. 
D (10-12) Within 2 min 
E (12-14) Within 2 min 
 
 
 
III-2-7- Best Master Formula  
 
 
According to the results, the best master formula is summarized in 
the following table (III-8) 
 
 
Table III-8: Best Master formula 
RM g % 
Fluconazole 50.00 40.0 
Avicel 102 31.00 24.8 
Lactose Spray Dried 38.75 31.0 
Aerosil 1.25 1.0 
Mg-Stearate 1.25 1.0 
Ac-di-sol 2.50 2.0 
Yellow Iorn Oxide 0.25 0.2 
Total 125.00 100.0 
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III-2-8- Production Step by step  
 
a-  Machines used 
 
Drum Mixer PM21 
Tableting Machine PM15 
Blistering Machine PM01 
 
b- Mixing Procedure 
 
1. Into a the drum mixer, add all materials except the 
Magnesium Stearate after passing them through 325 µm , 
and mix for 15 minutes.      
 
2. On the above mixture add Magnesium Stearate 
after passing through 325 µm, and mix for 5 
minutes. 
   
 
c- Compression 
 
Compress the prepared mixture using the Tableting 
machine 
 
Unit Weight:  250.0 mg 
Max. Wt.:  262.5 mg 
Min. Wt:  237.5 mg 
 
 
 
d-  Blistering  
Blister the tablets in a colorless PVC – Aluminum foil 
blisters using the blistering machine.  
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I I I -3 Dissolut ion Prof i le  
 
 
The dissolution Profile of  the best formula of Fluconazole tablet 
(Dican tablet), B.N R3G02 and manufacturing date 07/2002,  
was tested in vitro against the Trican capsule, B.N 257044 and 
expiry 03/2006 of Pfizer using the dissolution method described 
in II-2-3. The similarity factor between the two curves were 
calculated using the equation described in II-5.   
 
 
Table III-9: Dissolution values for 6 Dican tablets  
Minutes sa#1 sa#2 sa#3 sa#4 sa#5 sa#6 Average 
10 95.50 90.48 80.20 88.53 80.01 75.45 85.03 
15 99.88 95.97 86.84 94.35 98.20 98.96 95.70 
20 99.78 97.59 91.12 96.75 99.88 99.34 97.41 
25 101.20 98.28 96.15 97.35 100.28 100.31 98.93 
30 101.43 98.64 99.21 98.10 101.54 101.68 100.10 
40 100.98 100.75 98.62 97.81 100.19 101.07 99.90 
45 101.21 97.19 98.41 95.94 98.15 96.62 97.92 
 
 
 
Table III-10: Dissolution values for 6 Trican capsules 
Minutes sa#1 sa#2 sa#3 sa#4 sa#5 sa#6 Average 
10 41.65 86.27 49.74 49.1 42 75.1 57.31 
15 56.77 96.59 68.86 70.20 64.7 91.00 74.69 
20 71.99 106.51 87.18 85.00 84.00 99.36 89.01 
25 86.58 106.05 96.38 89.80 89.00 100.20 94.67 
30 97.72 109.36 103.92 98.00 92.10 102.70 100.63 
40 101.88 103.48 101.66 100.80 93.00 102.00 100.47 
45 101.63 107.03 103.05 100.80 93.30 101.00 101.13 
 
 
The average of the dissolution points for both the test and the 
reference samples is calculated and the F2 is then calculated. 
The first 25 minutes data only  were put in calculation (5 
minutes above the time in which 85 % dissolution occurs). The 
two profile are summarized in (figure III-1). 
 
Table III-11: Average dissolution values for Trican capsules and Dican 
tablets 
 10 min. 15 min 20 min 25 min 30 min. 40 min. 45 min. 
Dican 85.03 95.70 97.41 98.93 100.10 99.90 97.92 
Trican 57.31 74.69 89.01 94.67 100.63 100.47 101.13 
 
 
F2= 50 log {[1+(1/n) Σn t=1(Rt-Tt)2]-0.5  x 100} = 44.1 
Limits: 50 – 100 
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Result:  
When calculating the similarity factor in the range 10 – 25 minutes, 
the result fails (f2 = 44.1). This is due to the capsule shell of Trican 
capsules, which delays the dissolution in the first 5 minutes.  
 
The similarity factor calculated in the range 15 – 25 minutes was 
found to be within limits (f2=51.2). 
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Figure III-1: Average dissolution profiles of Dican tablet and Trican capsule 
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I I I -4  The Final  Product Speci f ication  
 
The final product was analyzed according to the procedure 
described in II-2. The results are summarized in the following 
table (III-12). All the results were according to the 
specifications. 
 
 
 
Table III-12: Analysis results for Dican tablet B.N R3G02 
 
 
Test Result Specification 
Shape Triangular 
tablets 
Triangular tablets 
Unit weight 256 251 ± 12.5 mg 
Color  Beige color Beige color 
Odor  Odorless Odorless 
Diameter 9.0 mm 9.0 ± 0.5 mm 
Average Hardness  11.5 K  Min. 4.0 K  
Friability < 0.1% Max. 1.0 % 
Assay 96.3 % 90.0 – 110 % 
Dissolution 99.6 % Min. 80.0 % in 45 minutes 
Weight uniformity Average wt ± 5% Average wt ± 5% 
Content uniformity Conforms Conforms 
Purity Pure Pure 
Chipping and capping No capping No capping 
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I I I -5 Val idation of the Test Method 
 
 
III-5-1 Selectivity 
 
 
A standard, sample and placebo solutions were analyzed 
under the same conditions as described in II-3-1. The 
chromatograms shows Figures (III-2, III-3, III-4) that there is 
only the active ingredient peak in the chromatograms. The 
placebo solution chromatogram showed no peak for any of 
the inactives in it. The same is for the selectivity under stress 
condition. Thus the procedure is selective for the proposed 
formula.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     Figure III-2: Chromatogram for the standard solution 
 
 
 
Peak information: 
Purity: 0.9980 
Asymmetry: 0.9454 
Theoretical plates (EUP): 1946 
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              Figure III-3: Chromatogram for the sample solution 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                 Figure III-4: Chromatogram for the placebo solution 
 
 
 
Table III-13: Selectivity after stress conditions after 48 hours 
Solvent Assay at 0 
time 
Assay after 
48 hours 
Other Peaks 
than 
Fluconazole 
Purity Check 
5N HCl 100.0 % 100.0 % None 0.9969 
5N NaOH 100.0 % 102.5 % Yes 0.9977 
30 % H2O2 100.0 % 97.2 % None 0.9994 
Boiling in H2O 100.0 % 100.0% None 0.9966 
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Figure III-5: Chromatogram for the HCl and Fluconazole  solution 
 
 
 
 
 
 
 
 
 
Figure III-6: Chromatogram for the HCl solution 
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Figure III-7: Chromatogram for the NaOH and Fluconazole solution 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III-8: Chromatogram for the NaOH solution 
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Figure III-9: Chromatogram for the H2O2 and Fluconazole solution 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III-10: Chromatogram for the H2O2 solution 
 
 
 
60 
 
 
III-5-2 Accuracy and Precision 
 
 
Five samples were prepared and analyzed three times, one time per 
day. Two injections of each sample were made. The active 
percentage was calculated for each sample and the average for the 
five samples was calculated for each day. Standard deviation (ST. 
DEV.), Coeffecient of variation (COEF. VAR.) and % of recovery (% 
RECOV.) were calculated for each day. The results were compared 
to the specification and the results were obtained for each day. The 
three day average of the coefficient variation (Precision) and the 
percentage of recovery (Accuracy) were calculated and compared 
with the limits. 
 
All data obtained for each day and the average data were with in 
specification specified. Thus, the method is considered accurate and 
precise. 
 
 
The data is shown in the following tables (III-14, III-15, III-16, III-17) 
 
 
 
 
Table III-14: Accuracy and precision analysis results for the first day 
 
 
 
Sample No. 
Standard Peak Area Sample Peak Area 
 % Assay 
INJ. No. 1 INJ. No. 2 Average INJ. No. 1 INJ. No. 2 Average 
I 291.41 292.33 291.87 286.50 286.00 286.25 98.07 
II 287.05 286.91 286.98 281.85 281.06 281.45 98.07 
III 289.71 292.37 291.04 290.00 290.30 290.15 99.69 
IV 289.79 292.52 291.16 292.65 294.39 293.52 100.81 
V 291.07 291.88 291.48 292.28 291.52 291.90 100.15 
Coefficient of  Variation 1.25 Max 1.50 Pass 
% Recovery 99.36 98.00 -102.00 Pass 
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Table III-15: Accuracy and precision analysis results for the second day 
 
 
 
 
 
 
Table III-16: Accuracy and precision analysis results for the third day 
 
 
 
 
 
 
 
Table III-17: 3 Days average of the accuracy and precision. 
 
 
 
 
 
 
Sample No. 
Standard Peak Area Sample Peak Area 
 % Assay 
INJ. No. 1 INJ. No. 2 Average INJ. No. 1 INJ. No. 2 Average 
I 293.14 291.04 292.09 294.92 292.79 293.86 100.60 
II 293.04 294.38 293.71 294.65 294.14 294.40 100.23 
III 289.45 291.24 290.35 295.22 294.24 294.73 101.51 
IV 294.34 293.31 293.83 297.08 295.08 296.08 100.77 
V 293.22 295.08 294.15 290.41 293.00 291.71 99.17 
Coefficient of  Variation 0.85 Max 1.50 Pass 
% Recovery 100.46 98.00 -102.00 Pass 
Sample No. 
Standard Peak Area Sample Peak Area 
 % Assay 
INJ. No. 1 INJ. No. 2 Average INJ. No. 1 INJ. No. 2 Average 
I 291.76 292.84 292.30 291.75 291.64 291.70 99.79 
II 292.81 290.11 291.46 291.33 292.46 291.90 100.15 
III 294.11 292.99 293.55 291.77 292.33 292.05 99.49 
IV 293.34 295.86 294.60 292.65 293.85 293.25 99.54 
V 295.65 293..63 295.65 293.63 290.58 292.11 98.80 
Coefficient of  Variation 0.50 Max 1.50 Pass 
% Recovery 99.55 98.00 -102.00 Pass 
Parameter Statistical Measure Result Limit Result 
Precision Coefficient of Variation 0.87  Max 1.50 Pass 
Accuracy % of Recovery 99.79 98.00 -102.00 Pass 
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III-5-3 Linearity 
 
Five samples were prepared with concentrations between 60 % and 
140 % from the assay concentration (15 mg / ml). Two injections 
were made for each concentration. Calculation was made for the 
coefficient of variation and y-intercept.  
 
All results were according to the specification. Thus we can conclude 
that the method is linear at the range of 60 – 140 % from the assay 
concentration. 
 
The data for linearity are represented in table (III-18) and Figure (III-
11).  
 
 
Table III-18: Linearity analysis results. 
%Conc. (mg/ml) 
Sample Peak Area 
Inj.1 Inj.2 Average 
9.00 174.29 175.93 175.11 
12.00 233.98 234.23 234.11 
15.00 294.18 293.84 294.01 
18.00 350.57 352.77 351.67 
21.00 408.51 408.49 408.50 
Average Area   292.68 
Correlation Coefficient 0.99995 Pass Min. 0.9998 
Y-Intercept 0.507 Pass 
± 5.85  
(± 2% of the average area) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III-11: Linearity curve 
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III-5-4 Range 
 
According to the linearity data, the method is linear on the 
range of 60 % - 140 % 
 
 
III-5-5 Robustness 
 
 
1- Two Different Analysts 
 
 
 
Table III-19: Robustness-two different analysts. 
Analyst 
Standard Peak Area Sample Peak Area 
% Assay 
Inj. No. 1 Inj. No. 2 Average Inj. No. 1 Inj. No. 2 Average 
Analyst 1 294.24 292.21 293.23 294.94 295.30 295.12 100.65 
Analyst 2 294.28 290.88 292.58 289.70 293.90 291.80 99.73 
Coefficient of 
Variation 0.64  Max 1.50 Pass 
 
 
 
2- Different Elapsed Assay Time 
 
 
 
Table III-20: Robustness-different elapsed assay time. 
Time 
Standard Peak Area Sample Peak Area 
% Assay 
Inj. No. 1 Inj. No. 2 Average Inj. No. 1 Inj. No. 2 Average 
10 min. 294.28 290.88 292.58 289.70 293.90 291.80 99.73 
4 hours 292.81 292.23 292.52 292.59 290.25 291.42 99.62 
Coefficient of 
Variation 0.08  Max 1.50 Pass 
 
 
3- Different Sonicating Time 
 
Table III-21: Robustness-different sonicating time 
Time 
Standard Peak Area Sample Peak Area 
% Assay 
Inj. No. 1 Inj. No. 2 Average Inj. No. 1 Inj. No. 2 Average 
10 min. 293.90 290.14 292.02 291.05 293.09 292.07 100.02 
15 min. 289.67 293.95 291.81 292.26 293.76 293.01 100.41 
20 min. 292.45 293.83 293.14 293.61 290.29 291.95 99.59 
Coefficient of 
Variation 0.28  Max 1.50 Pass 
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4- Different Columns 
 
 
Table III-22: Robustness-different columns 
Column 
Standard Peak Area Sample Peak Area 
% Assay 
Inj. No. 1 Inj. No. 2 Average Inj. No. 1 Inj. No. 2 Average 
# 1 289.67 293.95 291.81 292.26 293.76 293.01 100.41 
# 2 289.93 290.02 289.98 291.84 294.78 293.31 101.15 
Coefficient of 
Variation 0.52  Max 1.50 Pass 
 
 
 
 
 
 
5- Different Instruments 
 
 
Table III-23: Robustness-different instruments 
Instrument 
Standard Peak Area Sample Peak Area 
% Assay 
Inj. No. 1 Inj. No. 2 Average Inj. No. 1 Inj. No. 2 Average 
RI002 281.70 279.12 280.41 278.71 278.84 278.78 99.42 
RI001 294.29 290.88 292.59 289.70 293.09 291.40 99.59 
Coefficient of 
Variation 0.13  Max 1.50 Pass 
 
 
 
 
III-5-6 Conclusion: 
 
As the above data indicates, the method of analysis for Dican 
tablet is valid and pass all the criteria predetermined. 
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I I I -6 Stabi l i ty summary of data and resul ts  
 
 
III-6-1Effect of accelerated condition (T=40±2 ºC, RH= 75±5) 
 
Three batches were studied under accelerated conditions (T=40 ºC, 
RH= 75. The samples were packed in PVC-Aluminum blisters and 
incubated for six months. Analysis were performed at 0, 1, 3 and 6 
months. The results were compared with the specifications 
predetermined. The results of each batch are summarized in tables 
(III-24, III-25 and III-26). 
 
 
Table III-24: Accelerated stability (40 ºC, 75 RH) analysis data for B.N. R3G02 
Testing parameters 
Initial 
Result 
After 1 
Months 
After 3 
Months 
After 6 
Months 
Limits 
Identification (RT min) Complies  Complies Complies Complies Complies 
Assay 96.3 % 95.6 % 93.8 % 95.9 % (90.0-110.0)% 
Dissolution 91.2 % 
95.6 % 
88.8 % 93.2 % 
Min 80.0% in 45 
minutes 
Appearance tests Complies Complies Complies Complies Beige color, Pure 
Hardness 11.5 K 13.0 K 14.0 K 14.0 K Min 4.0 K 
Odor Odorless Odorless Odorless Odorless Odorless 
 
 
Table III-25: Accelerated stability (40 ºC, 75 RH) analysis data for B.N. R4G02 
Testing parameters 
Initial 
Result 
After 1 
Months 
After 3 
Months 
After 6 
Months 
Limits 
Identification (RT min) Complies  Complies Complies Complies Complies 
Assay 98.1 % 94.0 % 94.6 % 94.0 % (90.0-110.0)% 
Dissolution 91.3 % 
93.8 % 
103.0 % 95.6 % 
Min 80.0% in 45 
minutes 
Appearance tests Complies Complies Complies Complies Beige color, Pure 
Hardness 11.0 K 13.0 K 14.1 K 14.0 K Min 4.0 K 
Odor Odorless Odorless Odorless Odorless Odorless 
 
 
Table III-26: Accelerated stability (40 ºC, 75 RH) analysis data for B.N. R5G02 
Testing parameters 
Initial 
Result 
After 1 
Months 
After 3 
Months 
After 6 
Months 
Limits 
Identification (RT min) Complies  Complies Complies Complies Complies 
Assay 98.9 % 96.3 % 99.5 % 101.2 % (90.0-110.0)% 
Dissolution 91.3 % 96.4 % 
100.5 % 
98.8 % 
Min 80.0% in 45 
minutes 
Appearance tests Complies Complies Complies Complies Beige color, Pure 
Hardness 11.0 K 11.5 K 13.5 K 13.5 K Min 4.0 K 
Odor Odorless Odorless Odorless Odorless Odorless 
 
As the tables indicate, all results fit with in specifications with no 
significant changes. 
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III-6-2 Effect of intermediate condition (T=30 ±2 ºC, RH= 
60±5) 
 
 
Three batches were studied under intermediate conditions (T=30 ºC, 
RH= 60. The samples were packed in PVC-Aluminum blisters for six 
months. Analysis were performed at 0, 1, 3 and 6 months. The results 
were compared with the specifications predetermined. The results of 
each batch are summarized in tables (III-27, III-28 and III-29). 
 
 
 
Table III-27: Accelerated stability (30 ºC, 60 RH) analysis data for B.N. R3G02 
Testing parameters 
Initial 
Result 
After 1 
Months 
After 3 
Months 
After 6 
Months 
Limits 
Identification (RT min) Complies  Complies Complies Complies Complies 
Assay 96.3 % 95.1 % 94.5 % 96.8 % (90.0-110.0)% 
Dissolution 91.2 % 
95.8 % 
100.4 % 99.0 % 
Min 80.0% in 45 
minutes 
Appearance tests Complies Complies Complies Complies Beige color, Pure 
Hardness 11.5 K 12.0 K 10.5 K 14.0 K Min 4.0 K 
Odor Odorless Odorless Odorless Odorless Odorless 
 
 
 
Table III-28: Accelerated stability (30 ºC, 60 RH) analysis data for B.N. R4G02 
Testing parameters 
Initial 
Result 
After 1 
Months 
After 3 
Months 
After 6 
Months 
Limits 
Identification (RT min) Complies  Complies Complies Complies Complies 
Assay 98.1 % 93.5 % 92.9 % 94.3 % (90.0-110.0)% 
Dissolution 91.3 % 
95.5 % 
91.4 % 92.4 % 
Min 80.0% in 45 
minutes 
Appearance tests Complies Complies Complies Complies Beige color, Pure 
Hardness 11.0 K 11.0 K 10.6 K 11.0 K Min 4.0 K 
Odor Odorless Odorless Odorless Odorless Odorless 
 
 
Table III-29: Accelerated stability (30 ºC, 60 RH) analysis data for B.N. R5G02 
Testing parameters 
Initial 
Result 
After 1 
Months 
After 3 
Months 
After 6 
Months 
Limits 
Identification (RT min) Complies  Complies Complies Complies Complies 
Assay 98.9 % 94.5 % 102.2 % 99.3 % (90.0-110.0)% 
Dissolution 91.3 % 100.2 % 
101.8 % 
100.4 % 
Min 80.0% in 45 
minutes 
Appearance tests Complies Complies Complies Complies Beige color, Pure 
Hardness 11.0 K 11.7 K 12.0 K 13.0 K Min 4.0 K 
Odor Odorless Odorless Odorless Odorless Odorless 
 
 
As the tables indicate, all results fit with in specifications with no 
significant changes. 
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III-6-3 Effect of Light 
 
One batch was kept under direct light for 7 months, 24 hours per 
day. The samples were re-analyzed and compared with 
specification. The color was removed from the formula of this 
batch analyzed to eliminate any possible protection of the coloring 
agent used in the formula.  The results are indicated in table (III-
30) 
 
 
Table III-30: Effect of light analysis data for B.N. R1G02 
Testing Parameter Initial Result After 7 months Limits 
Identification Complies Complies Complies 
Assay 98.1 % 97.4 % (90.0-110.0)% 
Dissolution 93.6 % 94.3 % 
Min 80.0% in 45 
minutes 
Appearance tests White, Pure White, Pure White, Pure 
Hardness 11.0 K 13.0 K Min 4.0 K 
 
 
 
As the table indicates, all results fit with in specifications with no 
significant changes. 
 
 
 
 
III-6-4 Conclusion 
 
   
According to the above data, there is no significant change in the 
chemical and physical properties of Dican 100 tablet when exposed 
to different accelerated conditions and to the direct light. As a result, 
the formula is stable and can be given two year of expiration date at 
normal conditions (15-30ºC) when packed in PVC-Aluminum blisters.  
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I I I -7 Bioequivalence Data 
 
The bioequivalence study was done in Tanta University, Egypt. 
The summary of the results were as follows: 
 
 
III-7-1 Pharmacokinetic results 
 
 
The peak plasma concentration (Cmax) of Fluconazole following the 
administration of two Dican tablets ranged from 1.748 – 5.021 
g/ml with a mean value of 3.088 ± 0.796 g/ml whereas, the Cmax 
of Fluconazole following the administration of one Diflucan capsule 
(Pfizer) ranged from 1.636 – 5.707 g/ml, with a mean value of 
2.777 ± 0.999 g/ml. The mean time to reach the peak 
concentration (tmax) was 1.979 ± 1.386 hr after administration of 
two Dican tablets and 3.395 ± 1.763 hr after administration of one 
Diflucan capsule. The area under the plasma concentration time 
curve (AUC0∞)  after administration of two Dican tablet ranged 
from 78.09 – 226.05 g.hr/ml, with a mean value of  142.5 ± 39.47 
g.hr/ml, while following administration of one Diflucan capsule, it 
ranged from 76.55 – 310.2 g.hr/ml, with a mean value of 149.3 ± 
60.333 g.hr/ml. The results obtained after administration of two 
Dican tablets were corrected by  a factor of 0.75. 
 
Table III-31: In-vivo pharmacokinetic results for Dican vs Diflucan 
Parameters Dican (Pharmacare) 
(Mean ±S.D) 
Diflucan (Pfizer) 
(Mean ±S.D) 
Cmax (g/ml) 3.088 ± 0.796 2.777 ± 0.999 
tmax (hrs) 1.979 ± 1.386 3.395 ± 1.763 
AUC 0∞     (g.hr/ml) 142.5 ± 39.47 149.3 ± 60.33 
 
 
Relative Bioavailability = 95.44 % (as calculated from the AUC) 
 
Tables (III-32 and III-33) Illustrates  the detailed pharmacokinetic 
parameters calculated after administration of two Dican tablets and 
one Diflucan capsules respectively. 
 
Figure III-12 illustrates the mean plasma concentrations after oral 
administration. 
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Table III-32: Pharmacokinetic parameters calculated after a single oral dose 
administration of two Dican tablets (each contains 100 mg Fluconazole)  to 24 
healthy male volunteers. 
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Table III-33: Pharmacokinetic parameters calculated after a single oral dose 
administration of one Diflucan capsule (each contains 150 mg Fluconazole)  
to 24 healthy male volunteers 
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Figure III-12: Mean plasma concentration of Fluconazole following a single oral dose administration of two Dican tablets 
and one Diflucan capsule (Mean ± S.E.M) 
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III-7-2 Assesment of bioequivalence 
 
The relative bioavailability of Fluconazole from Dican tablets 
compared to Diflucan capsules (Pfizer) was found to be 95.44 % as 
determined from the ratio of the AUC0∞ of both products. 
 
It can be concluded that oral Dican tablets and oral Diflucan 
capsules are bioequivalent, since both preparations have equivalent 
rate and extent of Fluconazole absorption. 
 
 
I I I -8 Microbial  comparison between the Dican and 
Trican (Dif lucan) for Pf izer.  
 
 
A potency test for Fluconazole was developed using the plate method 
using Candida Albicans as the test organism. Several media and 
solvents were tested for the best clear zones. Tables (III-34 and (III-
35) summarizes the different media and solvents with the zone rate of 
clearance. 
 
 
Table III-34: Zone clearance using different agar media 
Agar Media Zone Clearance 
Antibiotic medium # 19 + 
Antibiotic medium # 3 +++ 
Antibiotic medium # 1 + 
YGC ++ 
 
 
Table III-35: Zone clearance using different solvents 
Buffer type Zone Clearance 
Buffer I + 
0.1 N HCl + 
Buffer 10 ++ 
Methanol ++ 
 
 
 
The standard and test solution concentrations were as follows: 
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Conc. Low:   66.6 (g/ml)  
Conc. High: 200.0 (g/ml)  
 
5 plates were prepared as in the procedure (II-8). Each plate 
contains 4 wells with the following samples (UL, UH, SL and SH). 
The plates were incubated at 35C for 24 hours. The zone 
diameters were measured and the results were recorded, table 
(III-36). 
 
 
Table III-36: Zone diameters for each plate (mm) 
 UH SH UL SL 
Plate # 1 31 30 27 27 
Plate # 2 29 30 26 25 
Plate # 3 31 30 28 26 
Plate # 4 30 31 27 27 
Plate # 5 31 32 28 29 
Average 30.4 30.6 27.2 26.8 
 
 
Calculation: 
 
(UH + UL) – ( SH + SL) 
Log X = LDR  x              
 (SH - SL) + ( UH - UL) 
 
Dose ratio = 20.0 / 6.66 = 3 
LDR = 0.477 
 
Log X = 0.477 x (57.6 – 57.4) / (3.8 + 3.4) = 0.0131 
 
X= 1.031 
 
 
Conclusion: 
From the results obtained, Dican tablet (B.N. R3G02 and 
manufacturing date 07/2002) activity against Candida albicans is 
103.1 % compared to Trican capsule (B.N 257044 and Expiry 
03/2006). 
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I I I -9 Ant i -Microbial  Activi ty of  Fluconazole.  
 
 
III-9-1 MIC results for Fluconazole: 
 
The antimicrobial activity of Fluconazole was tested agaist 4 
bacterial strains using the procedure in II-9.  The results were as 
follows: 
 
 
a. Salmonella:  no inhibition for concentrations up to 1000 
μg/ml. 
 
b. Staphylococcus Aureus:  inhibition in tubes # 2, in which the 
concentration of Fluconazole is 250 μg/ml.  
 
c. Pseudomonas Aeruginosa: no inhibition for concentrations 
up to 1000 μg/ml 
 
d. Escherishia Coli: no inhibition for concentrations up to 1000 
μg/ml 
 
 
III-9-2 MIC results for Clarithromycin: 
 
 
Staphylococcus Aureus:  inhibition in tube # 4, in which the 
concentration of Clarithromycin is 36.5 μg/ml. 
 
 
III-9-1 Plate count  
 
Salmonella: 150 colonies in plate #2 = 1.25 x 103 bacteria / ml 
in the MIC test tubes. 
 
Staphylococcus Aureus: 53 colonies in plate #3= 4.4 x 103 
bacteria / ml in the MIC test tubes. 
 
Pseudomonas Aeruginosa: 52 colonies in plate # 3 = 4.3 x 103 
bacteria / ml in the MIC test tubes. 
 
Escherishia Coli: 35 in plate # 3 = 2.9 x 103 bacteria / ml in the 
MIC test tubes. 
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III-9-3 Calculation and Results 
 
 
The concentration of the broth solution of a microorganism inoculum’s 
equals (Conc. (bacteria / ml))= 
 
Plate count x 10No of plates / inoculum volume on plate (ml) 
 
The final dilution in each test tube after inoculation with 50 μl in 6 ml 
is calculated as follows= 
  
Conc. (bacteria/ml) x inoculum’s volume (ml)/ total volume (ml) 
 
The Final dilution of every bacterial strain is thus calculated as 
follows: 
 
1- Salmonella  
 
 
Conc. (bacteria / ml) = 150 x 102 / 0.1 ml = 15 x 104 bacteria/ml 
 
The final dilution = (15 x 104 bacteria / ml) x (0.050 ml) / (6 ml) 
= 1.25 x 103 bacteria / ml 
 
 
2- Staphylococcus Aureus 
 
 
Conc. (bacteria / ml) = 53 x 103 / 0.1 ml = 53 x 104 bacteria / ml 
 
The final dilution = (53 x 104 bacteria / ml) x (0.050 ml) / (6 ml) 
= 4.4 x 103 bacteria / ml 
 
3- Pseudomonas Aeruginosa: 
 
 
Conc. (bacteria / ml) = 52 x 103 / 0.1 ml = 52 x 104 bacteria / ml 
 
The final dilution = (52 x 104 bacteria / ml) x (0.050 ml) / (6 ml) 
= 4.3 x 103 bacteria / ml 
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4- Escherishia Coli 
 
 
Conc. (bacteria / ml) = 35 x 103 / 0.1 ml = 35 x 104 bacteria / ml 
 
The final dilution = (35 x 104 bacteria / ml) x (0.050 ml) / (6 ml) 
= 2.9 x 103 bacteria / ml 
 
III-9-4 Discussion and conclusion 
 
 
Fluconazole has activity against Staphylococcus Aureus with a MIC 
of = 250 μg/ml against 4.4 x 103 microorganisms / ml in tryptic soy 
broth (TSB). 
 
Clarithromycin has activity against Staphylococcus Aureus with a MIC 
of 36.5 μg/ml against 4.4 x 103   microorganisms / ml  in tryptic soy 
broth (TSB). 
 
Compared to Clarithromycin, which is indicated for S. Aureus, 
Fluconazole is about 14.6 % as active as Clarithromycin. 
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PART IV: CONCLUSION 
 
 
New generic formulation for Fluconazole 100 mg tablet was 
developed using the direct compression method. A complete 
qualitative and quantitative analysis was performed for the resultant 
tablets and found to be within specification predetermined. 
 
An HPLC method of analysis has been developed using a reversed 
phase stationary phase and a UV-detector. The method was 
validated and found to be selective, accurate, precise, and linear and 
withstand for the possible variations in instruments, tools and 
personnel.  
 
A comparative dissolution profile was made for the formulated (Dican) 
tablet vs the brand product Trican capsule. The similarity factor 
calculation was applied. When calculating the similarity factor in the 
range 10 – 25 minutes, the result fails (f2 = 44.1). This is due to the 
capsule shell of Trican, which delays the dissolution in the first 5 
minutes. The similarity factor calculated in the range 15 – 25 minutes 
was found to be within limits (f2=51.2). 
 
Stability testing was conducted at stress conditions. A study for the 
effect of light was also performed. All results were within 
specifications with no significant changes occurred. 
 
A bioequivalence study was performed for the tablets vs Diflucan 
capsule in the University of Tanta, Egypt. The formula proved to be 
bioequivalent to the brand product. 
 
A potency plate method for measuring the potency activity of 
Fluconazole was developed. A biological comparison between the 
tablet and Trican capsule was conducted using the developed 
method. The tablet proved to be similar in activity compared to the 
brand product. 
 
A test for antibacterial activity was performed using the minimum 
inhibitory concentration (MIC) method. The test was conducted 
against four bacterial strains. An activity was found against 
Staphylococcus Aureus. The results were compared with that 
obtained from MIC for Clarithromycin. The activity was about 14.6 % 
compared to Clarithromycin. 
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